

DEPARTMENT/SCHOOL: Medicine

NAME: SUSAN F. DENT, BSc., MD, FRCPC
Medical Oncologist, Duke Cancer Institute
Professor of Medicine
Associate Director of Breast Cancer Clinical Research
Co-Director Duke Cardio-Oncology Program

ADDRESS: Primary address
Division of Medical Oncology
10 Brian Searle Drive
Seeley G. Mudd Bldg. Room 455
Durham, North Carolina
27710

Email: susan.dent@duke.edu
Tel: 919-6845734

MEDICAL DEGREES AND DIPLOMAS

1993 – 1995 Certificate of Special Competence, Medical Oncology, Royal College of Physicians & Surgeons of Canada
1990 – 1993 FRCPC, Internal Medicine, Royal College of Physicians & Surgeons of Canada
1987 – 1990 Doctorate in Medicine, McMaster University
1986 – 1987 Master studies, Kinanthropology, University of Ottawa
1982 – 1986 B.Sc Kinanthropology, Cum Laude, University of Ottawa

EMPLOYMENT HISTORY

Present Academic and Teaching Appointments

September 2018- present Professor, Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina
May, 2016 – Aug, 2018 Professor, Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ontario
Sep 2007 – April, 2016 Associate Professor, Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ontario
2003 – present Executive Member, Medical Oncology Associates, Ottawa, Ontario.
Dec 2000 – present Staff Medical Oncologist and Clinical Investigator, Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Previous Academic and Teaching Appointments

2014- Oct 2016 Vice-Chair Patient Quality and Clinical Services, Department of Medicine, University of Ottawa, Ottawa, Ontario

2012 – 2014	Vice-Chair Patient Quality and Safety Committee, Department of Medicine, University of Ottawa, Ottawa, Ontario
Dec 2000 – Sep 2007	Assistant Professor, Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ontario
Dec 2000 – Jun 2007	Head of Clinical Trials Department, Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Ontario
Jun 2002 – Dec 2003	Acting Head, Division of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario
Jan 1999 – Dec 2000	Research Coordinator, Family Medicine Residents, Northern Ontario Medical Program, Thunder Bay, Ontario
Oct 1998 – Dec 2000	Assistant Clinical Professor, Department of Medicine, Division of Medical Oncology, McMaster University, Hamilton, Ontario
Feb 1997 – Dec 2000	Consultant, Department of Medicine, Lake Woods District Hospital, Kenora, Ontario
Jul 1996 – Dec 2000	Staff Medical Oncologist, Northwestern Ontario Regional Cancer Centre, Thunder Bay, Ontario
Jul 1996 – Dec 2000	Medical Director, Clinical Trials Department, Northwestern Ontario Regional Cancer Centre, Thunder Bay, Ontario
Jul 1996 – Dec 2000	Consultant, Department of Medicine, Riverside Health Care Facility, Fort Frances, Ontario; and Dryden District General Hospital, Dryden, Ontario
Jul 1995 – Jun 1996	Medical Oncologist, Locum, Northwestern Ontario Regional Cancer Centre, Thunder Bay, Ontario
1995 – 1996	Hoffman La-Roche Fellow, National Cancer Institute of Canada, Clinical Trials Group, Queens University, Kingston, Ontario
1994 – 1995	Chief Resident, Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Ontario
1993 – 1994	Resident, Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Ontario
1991 - 1993	Resident, Internal Medicine, The Ottawa Hospital, Ottawa, Ontario
1990 – 1991	Comprehensive Intern, Internal Medicine, The Ottawa Hospital, Ottawa, Ontario

HONOURS

2017	Nomination for Human Touch Awards, Cancer Care Ontario, Ontario
2016	Department of Medicine Vision Award Nomination, The Ottawa Hospital
2015	COMPASS Award Nomination, The Ottawa Hospital, Ottawa, Ontario
2010-2015	Ottawa Hospital Guardian Angel Physician award x 5
2013	Innovation award, Ottawa Cardiac Oncology Program The Ottawa Hospital, Cancer Quality Council of Ontario and Canadian Cancer Society
2013	Best Multi-Tasker Award - Oncology Nurses, The Ottawa Hospital Cancer Centre
2013	Mentor of the Month award, Women in Cancer (WinC)

1995 Best oral presentation, Resident Research Day, Department of Medicine, University of Ottawa

Honours and Prizes to students/residents/fellows under my supervision

Freya Crawley Thesis Committee, MSc Nursing, University of Ottawa

Law W (student) Undergraduate Research Opportunity Program (UROP) award, University of Ottawa 2014

Sulpher J (fellow) Best oral presentation, Department of Medicine Residents Research Day 2014

Rushton M (resident) Best oral presentation, Department of Medicine Residents Research Day 2013; oral presentation Canadian Association of Medical Oncologists 2013; PSI research award 2014

Zhu X (resident) Best oral presentation, Department of Medicine Residents Research Day 2012

Dattilo F (student) Undergraduate Research Opportunity Program (UROP) award, University of Ottawa, 2012

Kwon A (resident) Best oral presentation, Department of Medicine Residents Research Day, 2012

Visram H (resident) Poster presentation award winner, Department of Medicine Residents Research Day, 2009 and 2010

Song X (fellow) Canadian Breast Cancer Foundation (CBCF) fellowship award – fellowship supervisor 2006-2007

PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Reviewer/Editor of scientific journals and grant panels

2018
Reviewer, Journal of Women's Health
Guest Editor, Breast and Lung Cancer Supplement. Current Oncology, Vol 25, June (2018)
Reviewer, JAMA Cardiology
Reviewer, Clinical Breast Cancer
Reviewer, Expert Review of Anticancer Therapy

2017
Reviewer, Health Research Board Grants, University of College, Dublin

2017
Reviewer, British Journal of Cancer

2017
Reviewer, Circulation
Reviewer, Indian Heart Journal

2016
Guest Editor, Special Issue on Cardio-oncology: Canadian Journal of Cardiology

2015-2016
Document Reviewer, 2016 Position Paper on cancer treatments and cardiovascular toxicity. (European Society of Cardiology)

2016
Reviewer, Population Health Research Institute grants, McMaster University

2015- present
Reviewer, Canadian Journal of Cardiology

2015 – present
Reviewer, American Heart Journal

2014 – present
Reviewer, Journal of Clinical Oncology

2012 – present
Reviewer, European Journal of Cancer

2009 – present
Reviewer, Current Oncology

2009 – present
Reviewer, Cancer

2008 – present
Reviewer, Breast Cancer Research and Treatment

2007 – present
Reviewer, Annals of Oncology

2007 – present
Reviewer, The Oncologist

2007 – present
Reviewer, BioMed Central Cancer

2005 – 2008
Reviewer, Lung Cancer

2015 – present
Associate Editor – Cardio-oncology (launched 02/15- www.cardiooncologyjournal.com)

2015-
Reviewer, Position Paper on Cancer Treatments and Cardiovascular Toxicity, European Society of Cardiology

2014 –2015	Lead Guest Editor – Journal of Oncology (special issue on cardio-oncology)
2011 – present	Reviewer, CIHR Grant Review Panel, Randomized control trials
2007 – present	Reviewer, Canadian Breast Cancer Foundation – Ontario Chapter
2014	External Advisory Panel, CAPRI cardio-oncology grant, Alberta
2013	Reviewer, Alberta Cancer Foundation Transformative Program competition
2012	Reviewer, Breast Cancer Campaign
2011	Reviewer, Flemish League against Breast Cancer
2011	Reviewer, Medical Advisory Secretariat of the Ontario Ministry of Health and Long-Term Care

Reviewer for Non-Peer-Reviewed Journals/Books

2009 – present	Reviewer, Oncology Exchange
2009	Reviewer of “Summary of Clinical Information for Abraxane”; a research report for Abraxis Bioscience Canada Inc.
2008	Medical Education Network Priority Press
2007	New Evidence, Canadian Vision for Oncology
2007	Ministry of Health Long Term Care

Medical and Scientific Memberships

2016 -	Faculty member Oncology Education: Breast Cancer and Cardio-Oncology
2014 – present	Member, European Society of Medical Oncology (ESMO)
2014 – present	President, International Cardio-oncology Society (ICOS) – Canada (www.icosna.org)
2011 – present	Founder and President , Canadian Cardiac Oncology Network (CCON) (www.cardiaconology.ca)
2000 – present	Member, Canadian Association of Medical Oncology (CAMO)
1996 – present	Active Member, American Society of Clinical Oncology (ASCO)
1996 – present	Fellow, Royal College of Physicians & Surgeons of Canada
1996 – present	Member, Ontario Medical Association
1996 – present	Member, Canadian Physicians & Surgeons of Ontario

COMMITTEE PARTICIPATION

Hospital/University Committees

2015- present	CaRMS R1, Internal Medicine applications - reviewer
2015 – 2016	Member, Evidence-based Cost-Effective Academic Care Team, Department of Medicine, University of Ottawa, Ottawa, Ontario
2015 –2016	Member, Career Development Team, Department of Medicine, University of Ottawa, Ottawa, Ontario
2014- 2016	Member, Resident’s Research Day Oral Presentations Judging Committee, Department of Medicine, University of Ottawa, Ontario
2012 – present	Member, Department of Medicine Executive Committee, University of Ottawa, Ottawa, Ontario
2012 –2015	Member, Quality and Performance Council, The Ottawa Hospital, Ottawa, Ontario
2011 – present	Head of Clinical Research, Breast Disease Site Group, The Ottawa Hospital Cancer Centre, Ottawa, Ontario
2008 – present	Co-Director, Ottawa Cardio-Oncology Program & Clinic, The Ottawa Hospital, Ottawa, Ontario
2008 – present	Chair, Breast Executive Committee, The Ottawa Hospital Cancer Centre, Ottawa, Ontario
2003 – 2013	Member, Medical Oncology Training Program Postgraduate Committee,

The Ottawa Hospital Cancer Centre, Ottawa, Ontario

- 2000 – 2013 Member, Clinical Research Executive, The Ottawa Hospital Cancer Centre, Ottawa, Ontario
- 2006 – 2012 Member, Phase I Disease Site Committee, The Ottawa Hospital Cancer Centre, Ottawa, Ontario
- 2004 – 2007 Member, Leadership Continuing Education Advisory Group, The Ottawa Hospital, Ottawa, Ontario
- 2004 – 2007 Member, Privacy & Research Committee, The Ottawa Hospital, Ottawa, Ontario
- 2002 – 2007 Member, Governing Council for Clinical Research, The Ottawa Hospital, Ottawa, Ontario
- 2002 – 2007 Member, Tumor Bank Local Management Committee, The Ottawa Hospital, Ottawa, Ontario
- 2001 – 2009 Chair, Clinical Research Evaluation Committee (CREC), The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Provincial Committee Participation

- 2011 – present Member, Systemic Therapy Serious Toxicity Working Group, Cancer Care Ontario, Toronto, Ontario
- 2004 – 2016 Consultant, Drug Quality & Therapeutics Committee, Ontario Ministry of Health, Toronto, Ontario
- 2003 – present Member, Breast Cancer Disease Site Group, Practice Guidelines Initiative Cancer, Care Ontario, Toronto, Ontario (Expert Panel member)
- 2007 – 2013 Systemic Lead, Cancer Care Ontario Regional Systemic Treatment Program, Champlain LHIN, Ontario
- 2007 – 2013 Member, Champlain & District Program Steering Committee, Champlain and District Health, Ontario
- 2003 – 2012 Member, Steering Committee for Ontario Cancer Research Ethics Board, Cancer Care Ontario, Toronto, Ontario
- 2003 – 2012 Co-Founder and member, Ontario Cancer Research Ethics Board (OCREB), Cancer Care Ontario, Toronto, Ontario
- 2007 – 2010 Ontario Institute of Cancer Research (OICR), Clinical Trials Advisory Council (TAC), Toronto, Ontario
- 2003 – 2010 Vice Chair, OCREB, Ontario Cancer Research Network (OCRN), Ontario

National Committee Participation

- 2011 – present Founder & Director, Canadian Cardiac Oncology Network (CCON)
- 2011 – 2016 Member, Clinical Guidance Panel Breast Cancer - Pan Canadian Oncology Drug Review (now Canadian Agency for Drugs and Technologies in Health)
- 2011 – 2015 Member, Randomized Controlled Trials Grants Committee, Canadian Institutes of Health Research (CIHR)
- 2005 – present Member, Breast Disease Site Group, National Cancer Institute of Canada Clinical Trials Group

2011 – 2014	Co-Chair, Annual Canadian Cardiac Oncology Network Conference Planning Committee
2011 – 2014	Member, Investigational new drugs breast cancer working group, National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario
2008-2013	Member, Executive Committee, National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario
2007-2013	Clinical Trials Centre Representative for the Ottawa Hospital Cancer Centre, National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario
2008	Chair, 2 ND Annual Locally Advanced Breast Cancer Meeting Planning Committee
2007	Co-Chair, Breast Cancer Conference, Quebec City, Quebec
2001-2007	Member Quality Assurance Committee National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario and lead auditor for 15 site visits across Canada

International Committees/Boards

2015 – present	Co-Chair, Cardiotoxicity Working Group, NCORP
2014 – present	Canadian Lead, International Cardiac Oncology Fellowship & Curriculum Development, Canadian Cardiac Oncology Network and International CardiOncology Society
2014 – 2016	Co-Chair, Global Cardio-Oncology Summit (2015,2016); Planning committee GCOS 2017
2014 – present	Member, Data Sharing Committee for Aphinity (International Phase III clinical trial in breast cancer)
2013 – present	Member, National Cancer Institute (NCI) Community Oncology Cardiovascular Task Force (U.S.)
2013 – present	Member, Eastern Cooperative Oncology (ECOG) Cardiotoxicity Working Group (U.S.)
2013 – present	President, International CardiOncology Society – Canada
2012 – present	Member, International Steering Committee, International Co-operative Group (BIG/NCIC) phase III randomized control trial of standard chemotherapy +/- pertuzumab in women with early stage HER2 positive breast cancer (APHINITY)
2015-2016	Co-Chair Working group 4: ASCO Cardiac Dysfunction Expert Panel Working Group

Other Memberships

2012 – present	Chair, Data Monitoring Safety Board, ICARUS Trial, Investigator led trial, Ottawa, Ontario
----------------	--

RESEARCH/EDUCATION CERTIFICATES

2014	Preparing your Promotion Application – Faculty of Medicine, University of Ottawa
2014	OHS Awareness Training for Supervisors
2011	Clinical Research Education Session, Health Canada Division 5/GCP and OHRI SOPs
2011	Champlain LHIN Senior Leadership Program, University of Toronto Rotman School of Management & University of Ottawa Telfer School of Management

RESEARCH PROJECTS

Ongoing Research Activities

- 2015 – present **Local Principal Investigator**, Hoffman-La Roche Limited - A phase III, double-blind, placebo controlled, randomized study of taseleisib + fulvestrant vs placebo + fulvestrant in post-menopausal women with ER positive and HER-2 negative locally advanced or metastatic breast cancer who have disease recurrence or progression.
- 2011 – present **National Principal Investigator (Canada) and Member of International Steering Committee** – A randomized multicenter trial, International, double-blind, placebo controlled comparison of chemotherapy plus Trastuzumab plus placebo versus chemotherapy plus Trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2 – positive primary breast cancer. Breast International Group (BIG).

Completed Research Projects

- 2014 – 2015 **Local Principal Investigator**, Celgene Corporation – A phase 2/3, multi-center, open-label, randomized study of weekly nab-paclitaxel in combination with gemcitabine or carboplatin, compared to gemcitabine/carboplatin, compared as first-line treatment in subjects with ER, PgR, and HER2 negative (triple negative metastatic breast cancer).
- 2013 – 2015 **Local Principal Investigator**, Ontario Clinical Oncology Group – A prospective cohort study to evaluate to evaluate the oncotype DX test in early stage breast cancer.
- 2013 – 2016 **Local Principal Investigator**, National Cancer Institute of Canada Clinical Trials Group, A randomized phase II study of reolysin for patients receiving standard weekly paclitaxel therapy as therapy for advanced/metastatic breast cancer.
- 2012 – 2015 **Local Principal Investigator**, Hoffman LaRoche Limited, BO25430, Open-Label Multicentre Extension Study of Trastuzumab Emtansine in Patients Previously Enrolled in a Genentech-and/or Hoffman-La Roche Ltd-Sponsored Trastuzumab Emtansine Study.
- 2012 – 2015 **Local Principal Investigator**, Hoffmann-La Roche Limited, BO24499, A phase I, open-label study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with impaired hepatic function.
- 2012 – 2014 **Local Principal Investigator** – An open label, randomized phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzamab treatment.
- 2010 – 2014 **Local Principal Investigator**, Hoffman-La Roche Limited, Phase 2 Study of Pertuzumab in Combination with Trastuzumab as Neoadjuvant Therapy for Patients with Locally Advanced, Inflammatory or Early Stage HER2-Positive Breast Cancer.
- 2008 – 2014 **Local Principal Investigator**, Hoffman LaRoche, A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
- 2011 – 2013 **Local Principal Investigator**, Geron Corporation, Phase 2 study of imetelstate with paclitaxel in locally or metastatic breast cancer.
- 2010 – 2012 **Local Principal Investigator**, National Clinical Institute of Canada Clinical Trials Group, Phase 2 study of fortinib in patients with estrogen receptor, progesterone receptor, and HER2 negative, recurrent/metastatic breast cancer.

- 2009 – 2012 **Local Principal Investigator**, National Cancer Institute of Canada Clinical Trials Group, A randomized, open-label, phase III study of taxane based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer.
- 2010 – 2011 **Principal Investigator**, Ottawa Regional Cancer Foundation, A prospective cohort study exploring urogenital toxicity and sexual dysfunction in women receiving endocrine therapy for early stage breast cancer.
- 2009 – 2011 **Local Principal Investigator**, Bristol-Myers Squibb, Phase I/III trial of BMS 754807 with trastuzumab in HER2 positive breast cancer.
- 2009 – 2010 **Local Principal Investigator**, The Ottawa Regional Cancer Foundation, Novel approaches to treatment of bone metastasis in breast cancer.
- 2008 – 2010 **Local Principal Investigator**, Array BioPharma Inc, Phase 2 study of arry-334543 with capecitabine in advanced breast cancer following phase 1 lead-in to assess arry-334543 with capecitabine in patients with advanced cancer.
- 2008 – 2009 **Principal Investigator**, Ottawa Regional Cancer Foundation, Clinical features and biological characteristics of women with basal-like (triple negative) breast cancer.
- 2007 – 2009 **Local Principal Investigator**, Canadian Breast Cancer Research Alliance, Patient-centered strategy to facilitate transition of breast cancer survivors routine follow-up (OCOG flupII).
- 2007 – 2009 **Local Principal Investigator**, Fresenius Medical Care Canada, The trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with Her-2/neu overexpressing (3+ by Dako Hercep Test or FiSH+) metastatic breast cancer progressing after trastuzumab treatment.
- 2007 – 2008 **Local Principal Investigator**, National Cancer Institute of Canada Sub Site, Advanced incurable malignancy (NCIC CTG IND.191).
- 2007 – 2008 **Local Principal Investigator**, Eli Lilly Canada Inc., Capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic breast cancer.
- 2007 – 2008 **Local Principal Investigator**, National Cancer Institute of Canada Clinical Trials Group, Proxopanib in patients with recurrent and/or metastatic invasive breast carcinoma.

RESEARCH FUNDING

External Research Funding

G= peer-reviewed grant; F=foundation; O=other

Year	Source	TYPE	Role	Amount	Title of Project
2014-2017	Canadian Breast Cancer Foundation – Ontario Chapter (PR)	G	Co-investigator	\$450,000	<i>The Cubic Trial: A window of opportunity trial evaluating the role of chloroquine and autophagy in breast cancer.</i>
2014	Patient Quality and Safety Committee Department of Medicine PI: M. Clemons	O	Co-investigator	\$20,000 \$10,000 match funds	<i>The React Study: Feasibility of suing an Integrated consent model to compare two standard of care regimens for primary prophylaxis of taxotere/cyclophosphamide induced febrile neutropenia</i>
2014	ORACLE Innovation Cluster Pilot Project Funding PI: L. Mielniczuk	F (Ottawa Heart Institute)	Co-investigator	\$40,000	<i>Elucidating the mechanisms of right heart failure</i>

2012-2014	Canadian Breast Cancer Foundation – Ontario Region (PR) PI: M. Clemons	G	Co-investigator	\$280,594	<i>A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bisphosphonate therapy in patients with metastatic breast cancer. The Achilles Study.</i>
2013	Patient Quality & Safety Committee, Department of Medicine, The Ottawa Hospital PI: D. Simos & M. Clemons	O	Co-investigator	\$20,000 <i>\$10,000 match funds oncology</i>	<i>Peri-operative imaging for metastatic disease in patients with operable breast cancer: improving both the quality and safety of patient care while decreasing costs</i>
2013	Patient Quality & Safety Committee, Department of Medicine, The Ottawa Hospital PI: C. Johnson	O	Co-investigator	\$20,000 <i>\$10,000 match funds oncology</i>	<i>The development of a predictive model to estimate cardiotoxic risk for patients receiving both anthracycline chemotherapy and trastuzumab</i>
2011-2013	Canadian Breast Cancer Foundation – Ontario Region (PR) PI: M. Clemons	G	Co-investigator	\$192,884 ongoing	<i>A randomized, double-blind, placebo-controlled, Phase III trial evaluating the palliative benefit of either continuing pamidronate or switching to second-line zoledronic acid in breast cancer patients with high-risk bone metastases (The Odyssey Trial)</i>
2011-2013	Canadian Breast Cancer Foundation – Ontario Region (PR) PI: M. Clemons	G	Co-investigator	\$145,125	<i>A Randomized, Phase III Trial of Individualized Care versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients (The Epic Trial)</i>
2010-2013	Canadian Breast Cancer Foundation – Ontario Region (PR) PI: M. Clemons	G	Co-investigator	\$288-500	<i>A multicentre phase II study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer using bone resorption markers (The Triumph Trial)</i>
2011	Shoppers Drug Mart The 2010 Tree of Life Annual Campaign PI: S. Dent (F)	O	Principal Investigator	\$42,233	<i>Evaluating adherence and toxicities in postmenopausal women with estrogen sensitive breast cancer prescribed aromatase inhibitors</i>
2010	Pfizer Pharmaceuticals PI: L. Paquet & X. Song (I)	O	Co-investigator	\$19,150	<i>Adherence to endocrine therapy in early breast cancer: Prevalence rates and psychosocial predictors</i>
2010	Abraxis BioScience (I) PI: S. Dent	O	Principal Investigator	\$5,000	<i>Evaluating the Efficacy and Toxicities of nab-Paclitaxel (Abraxane) in women with metastatic breast cancer</i>
2010	Pfizer Pharmaceuticals (I) PI: S. Dent	O	Principal Investigator	\$5,000	<i>Retrospective chart review of the incidence and management of sunitinib-induced cardiotoxicity in patients with renal cell carcinoma and gastro-intestinal stromal tumors</i>

Internal Research Funding

G=peer-reviewed grant; F=foundation; O=other

Year	Source	Type	Role	Amount	Title of Project
-------------	---------------	-------------	-------------	---------------	-------------------------

2014	Ottawa Regional Cancer Foundation (F)	F	Principal Investigator	\$49,500	<i>BioTIC: Biomarkers in Treatment induced cardiotoxicity – a feasibility study</i>
2010	Ottawa Regional Cancer Foundation	F	Principal Investigator	\$19,240	Assessment of the prevalence and severity of sexual dysfunction in women receiving Endocrine therapy for early-stage breast cancer
2008	Ottawa Regional Cancer Foundation PI: S. Dent	F	Principal Investigator	\$21,500	Clinical Features and biological characteristic of women with basal-type (Triple Negative) Breast Cancer

Program Funding

G=peer-reviewed grant; F=foundation; O=other

Year	Source	Type	Role	Amount	Title of Project
2014-present	ECOG-ACRIN Medical Research Foundation (U.S.) research sub-award	G	Co-Chair	\$9,704	<i>Cardiotoxicity work group to improve the understanding of cardiotoxicity of cancer therapeutics</i>
2013-2015	Hoffman La-Roche and the Ottawa Hospital Foundation (I, F)	O	Co-Director	\$160,000	<i>The Ottawa Hospital Cardio-oncology fellowship program (to support 2 year fellowship)</i>
2009-2011	Hoffman LaRoche, Pfizer (I) PI: S. Dent	O	Co-Director	\$45,000	<i>Establishment of a multidisciplinary Cardiac Oncology Clinic</i>
2007	Ottawa Regional Cancer Foundation	F	Co-Lead	\$20,000	<i>The development of an inter-professional locally advanced breast cancer clinic</i>

LEADERSHIP AND INNOVATIONS IN RESEARCH/EDUCATION

- 2012 – present Canadian Cardiac Oncology Fellowship
Co-Supervisor of the 1st Canadian Cardiac Oncology Fellowship at the Ottawa Hospital Cancer Centre. Developed training objectives and expectations for the one – two year fellowship. 1st fellow July, 2013-2015; 2nd fellow July 2015-June, 2017
- 2011 – present Founder and President, Canadian Cardiac Oncology Network (CCON)
A National organization dedicated to optimizing cardiac care for cancer patients receiving potentially cardiotoxic therapies. The CCON mission is to gain a better understanding of cardiac complications of oncology treatments, to develop early detection and intervention strategies to optimize cardiac health and to optimize patient outcomes by collaborating with allied health care professionals (www.cardiaconology.ca). We have developed a one-day cardio-oncology workshop with National and International Participants. CCON has linkages internationally with the International Cardiac Oncology Society (ICOS) and ICOS North America (www.icosna.org).
- 2008 – present Founder and Co-Director of a dedicated cardio-oncology clinic at The Ottawa Hospital – the first such clinic in Canada. In collaboration with 3 cardiologists and a pharmacist, we established a dedicated clinic (Ottawa Cardiac Oncology clinic) to care for cancer patients with pre-existing cardiac health issues or who develop cardiotoxicity related to their cancer treatments. In 2013 we received the Innovation award from the Cancer Quality Council of Ontario.
- 2008-present Chair, Junior Mentorship Program in Oncology (JUMP)
Mentorship program held annually for oncologists in their first 3 years of practice; 5 oncologists are selected each year and invited to spend 1.5 days with 5 mentors (from across Canada) to

discuss a variety of topics including: career goals, hot topics in oncology, how to prepare for promotion, and life-work balance. To date 45 mentees have attended this program.

2006 – 2007

Breast Cancer Fellowship

Supervisor of the 1st Breast Cancer Fellow at the Ottawa Hospital Regional Cancer Centre
In collaboration with Dr. Verma (Breast Cancer Disease Site Chair) developed training objectives and expectations for the one-year fellowship.

Successful in obtaining fellowship funding from the Canadian Breast Cancer Foundation, Ontario Chapter (\$69,000 over one year).

PUBLICATIONS

H-Index: 26

Papers in peer-reviewed journals.....	92
Book Chapter.....	3
Papers in non-peer-reviewed journals	30
Abstracts/Posters.....	139

Papers (peer-reviewed)

2018

1. Dang, C. Blaes A., Lynce F., Swain, **Dent, S.** Left Ventricular Ejection Fraction Monitoring Adherence Rates- Why so Low? Editorial. JACC imaging. Vol 11 No. 8. August 01, 2018 **Role: Senior author**
2. Le May M, **Dent S.** Anti-Yo Antibody mediated Paraneoplastic Cerebellar Degeneration associated with Cognitive Affective Syndrome in a patient with breast cancer: a case report and literature review. Accepted May 2018, Current Oncology, **Role: Senior author**
3. **Dent. S.F.** Progress in breast cancer – can we do better? Current Oncology, Vol. 25, No. 3, June 2018. **Role: First author.**
4. Bernstein V, Ellard S, **Dent S.** Et al A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: a final analysis of Canadian Cancer Trials Group IND.213 Breast Cancer Research and Treatment, : 167 (2): 485-493, 2018 Impact factor: **Role: Contributing author**
5. Laxmi S. Mehta,¹ MD, FAHA, Chair; Karol E. Watson,² MD, PhD, FAHA, Vice-Chair; Ana Barac,³ MD; Theresa Beckie, PhD,⁴ FAHA; Vera Bittner,⁵ MD, FAHA; Salvador Cruz-Flores,⁶ MD; **Susan Dent,**⁷ MD; Lavanya Kondapalli,⁸ MD; Bonnie Ky,⁹ MD; Tochukwu Okwuosa,¹⁰ MD; Ileana L. Piña,¹¹ MD, MPH; FAHA; Annabelle Volgman,¹⁰ MD; FAHA; on behalf of the American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology. Cardiovascular Disease and Breast Cancer: Where these Entities Intersect Circulation, Feb 1st, 2018, Impact factor: 19.3 **Role: Contributing author**

2017

6. Kelly F, Carroll L, Carley M, **Dent S,** Shore R, Hu J, Morash R. Stacey D. Symptom practice guide for telephone assessment of patients with cancer treatment-related cardiotoxic dyspnea: Adaptation and evaluation of acceptability. Cardio-Oncology 2017 **Role: Contributing author.**
7. Kelly F, Liska C, Morash R, Hu J, Carroll SL, Shorr R, **Dent S,** Stacey D. Shared medical appointments for patients with a non-diabetic physical chronic illness: A systematic review. Chronic Illness, publication August 10, 2017.
8. Aseyev O, Stober C, Sulpher J, Clemons M, Johnson C, Fergusson D, Vandermeer L, Mazzarello S, **Dent S.** Comparison of two care schedules for monitoring of cardiotoxicity in patients with trastuzumab-based therapy for early stage breast cancer: study protocol for a randomized controlled non-inferiority trial, Clinical Trials in Degenerative Diseases. Volume 2, Issue 2, June 2017. **Role: Senior author**
9. Rushton M, Johnson C, **Dent S** Trastuzumab Induced Cardiotoxicity—searching for a reliable means of predicting permanent cardiac dysfunction., Current Oncology, June 2017 Vol 24, No. 3, Impact factor: 2.47 **Role: Senior Author**
10. Law A, Johnson C, Rushton M, **Dent S** .Framingham Risk Score underestimates risk of cardiovascular events in HER2+ breast cancer population. Current Oncology. October 2017, Volume 24, number 5. . Impact factor: 2.47 **Role: Senior author.**

2016

11. Saro Armenian, Christina Lacchetti, Ana Barac, Joseph Carver, Louis Sandy Constine, Neelima Denduluri, **Susan Dent**, Pamela S. Douglas, Jean-Bernard Durand, Michael Ewer, Carol Fabian, Melissa Hudson, Mariell Jessup, Lee Jones, Bonnie Ky, Javid Moslehi, Erica L. Mayer, Kevin Oeffinger, Katharine Ray, Kathryn Ruddy and Daniel Lenihan. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology* 2016 Dec 5 Impact Factor: 18.37 **Role: Contributing author.**
12. Chunze Li, Priya Agarwal, Ekaterina Gibiansky, Jin Jin, **Susan Dent**, Anthony Gonçalves, Ihsan Nijem, Alexander Strasak, Marie-Laurence Harle-Yge, Nataliya Chernyukhin, Pat LoRusso, Sandhya Girish; A Phase I Pharmacokinetics Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. *Clin Pharmacokinet.* 2016 Dec 19 Impact Factor: 5.05 **Role: Contributing author**
13. Lenihan Dj, Dent S, Carver J. Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training. *J Card Fail.* 2016 Nov; 22 (11): Role: Contributing author.
14. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S; Authors/Task Force Members; ESC Committee for Practice Guidelines 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *European Journal of Heart Failure*; 2016 Aug 27. Impact Factor: 5.1 **Role: Document Reviewer**
15. Virani S*, **Dent S***, Brezden-Masley C, et. Al el Canadian Cardiovascular Society Guidelines for Evaluation and Management of Patients at Risk for Cardiovascular Complications of Cancer Therapy. *Canadian Journal of Cardiology* Volume 32 (7) July 2016. Impact Factor. 3.94 Role: **First author.** (* these authors contributed equally to this work)
16. Boczar K, Sulpher J, Johnson C, Al-Harbi I, Burwash I, Turek M, **Dent S**, Dwivedi G. Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. *Echo Research and Practice* July 2016. Impact factor not available: **Role: Contributing author.**
17. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, **Dent S**, Gelmon K, Paterson A, Rayson D, Berry DA. Association of Pathological Complete Response to Neoadjuvant Therapy in HER-2 Positive Breast Cancer with Long-Term Outcomes: A Meta-analysis. *JAMA Oncology* 2016 June 1 2 (6): 751-60. Impact factor not available **Role: Contributing author**
18. Arnaout A, Kuchuk I, Bouganim N, Pond G, Verma S, Segal R, **Dent S**, Gertler S, Song X, Kanji F, Clemons M. Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study. *Curr Oncol.* 2016 Jun;23(3):e276-9. 2016 Jun 9. Impact factor 2.5 **Role: Contributing author.**
19. Rayson D, Lupichuk S, Potvin K , **Dent S**, et.al. NCIC Clinical Trials Group IND197: A phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 negative recurrent or metastatic breast cancer. *Breast Cancer Research and Treatment*, April 2016. Impact factor 4.08 **Role: Contributing author.**
20. **Dent S.**, Aseyev O, Lenihan D. On-going research developments in Cardio-oncology. *OncoReview.* March 2016, Vol 6. Impact factor not available **Role: First Author.**
21. Daniel J. Lenihan, MD; Gregory Hartlage, MD; Jeanne DeCara, MD; Anne Blaes, MD; J. Emanuel Finet, MD; Alexander Lyon, MD; Frank Cornell, MD; Javid Moslehi, MD; Guilherme Oliveira, MD; Gillian Murtagh, MD; Michael Fisch, MD; Gary Zeevi, MD; Zaza Iakobishvili, MD; Ron Witteles, MD; Aarti Patel, MD; Eric Harrison, MD; Michael Fradley, MD; Giuseppe Curigliano, MD; Carrie Lenneman, MD; Andreia Magalhaes, MD; Ron Krone, MD; Charles Porter, MD; Susmita Parashar, MD; **Susan Dent**, MD; Pamela Douglas, MD; Joseph Carver, MD. Cardio-Oncology Training: A Proposal from the International CardiOncology Society and Canadian

Cardiac Oncology Network for a new multidisciplinary specialty. Journal of Cardiac Failure, 2016 March 30, Impact Factor: 3.0 **Role: Contributing author**

22. Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, **Dent S**, Gertler S, Song X, Wheatley-Price P, Dranitsaris G, Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: A randomized control trial. JAMA Oncol 2016 Feb 1; 2(2) 225-31 Impact factor: not available **Role: Contributing author**
23. Sulpher J, Kan K, Hopkins S, **Dent S**. Impact of a ciprofloxacin or G-CSF primary prophylaxis prescribing prompt for the prevention of febrile neutropenia in breast cancer patients receiving adjuvant docetaxel-cyclophosphamide chemotherapy – a retrospective analysis. Support Care Cancer. 2016 Mar 3. Impact factor 2.5 **Role: Senior responsible author**
24. Broglio K, Quintana , Foster M, Olinger M, McGlothlin A, Berry S , Boileau JF, Brezden-Masely C, Chia S, **Dent S**, Gelmon K, Paterson A, Rayson D, Berry D. Association of Pathologic Complete Response to Neoadjuvant Therapy for HER-2 –Positive Breast Cancer with Long-term Outcomes. **JAMA Oncology**, February 25th, 2016. Impact factor not available **Role: Contributing author**.
25. Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection and Management Giuseppe Curigliano MD PhD¹, Daniela Cardinale MD PhD², **Susan Dent MD³**, Carmen Criscitiello MD PhD¹, Olexiy Aseyev MD PhD³, Daniel Lenihan MD⁴ , Carlo Cipolla MD² Division of Experimental Therapeutics, Division of Medical Oncology ²Division of Cardiology, Cardio-Oncology Program, European Institute of Oncology, Milano, Italy; ³The Ottawa Hospital Cancer Centre, Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁴Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Accepted for publication: CA: A journal for clinicians published on line February 26th, 2016. **Impact factor: 144.8 Role: Contributing author**

2015

26. Rushton M, Crawley F, Sulpher J, Johnson C, **Dent S**. Cardiotoxicity in Breast Cancer Patients: A single centre, retrospective review. Progress in Pediatric Cardiology: volume 39; Issue 2, Part A; Nov 2015. 67-69. Impact factor not available. Role: **Senior Responsible Author**
27. Jacobs C, Kuchuk R, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, **Dent S**, Gertler S, Verma S, Song X, Demetrios S, Cella D, Clemons M. . A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. Breast Cancer Research and Treatment 2015 Dec 7[Epub ahead of print] PubMed PMID: 26643085 Impact factor 3.9 **Role: Contributing author**
28. **Dent S**, Liu P, Brezden-Masley Christine, Lenihan D. Cancer and Cardiovascular Disease: The Complex Labyrinth Journal of Oncology Special Issue. August 4 2015 Impact factor not available. **Role: First author.**
29. Simmons C, **Dent S**, Brezden-Masley C. Duration of trastuzumab, in matters of the heart, one size might not fit all? Accepted for publication. Eur J Cancer – Editorial. 2015 Jul 13 [Epub ahead of print]. Impact factor 4.819. **Role: Contributing author.**
30. Simos D, Catley C, van Walraven C, Arnaout A, Booth CM, McInnes M, Fergusson DA, **Dent S**, Clemons M. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015 Jun 22 [Epub ahead of print]. Impact factor 5.959. **Role: Contributing author**
31. Arnaout A, Kuchuk I, Bouganim N, Pond G, Verma S, Segal R, **Dent S**, Gertler S, Song X, M Namazi, Kanji F, and M Clemons. Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The ENHANCE Study. Accepted for publication. Current Oncology 2015. Impact factor 1.785. **Role: Contributing author**
32. Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, Stadnick E, Law A, Wentzell J, **Dent SF**. Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study. Accepted for publication. Journal of Oncology 2015 August 2 Impact Factor: Not Available. **Role: Senior Responsible Author.**
33. Sulpher J, Mathur S, Lenihan D, Johnson C, Turek M, Law A, Stadnick E, Dattilo F, Graham N, **Dent S**. An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic

therapy. Accepted for publication. Journal of Oncology 2015. Impact Factor: Not Available. **Role: Senior Responsible author.**

34. Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, **Dent SF**. Systemic targeted therapy for HER2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. *Curr Oncol.* 2015 Mar;22(Suppl 1):S114-122. Impact Factor: 1.785. **Role: Senior Responsible author.**
35. Freedman OC, Fletcher GG, Gandhi S, Mates M, **Dent SF**, Trudeau ME, Eisen A. Adjuvant endocrine therapy for early breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. *Curr Oncol.* 2015 Mar;22(Suppl 1):S95-113. Impact Factor: 1.785. **Role: Contributing author.**
36. Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, **Dent SF**, Trudeau ME. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. *Curr Oncol.* 2015 Mar;22(Suppl 1):S82-94. Impact Factor: 1.785. **Role: Contributing author.**
37. Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, **Dent SF**, Trudeau ME; members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. *Curr Oncol.* 2015 Mar;22(Suppl 1):S67-81. Impact Factor: 1.785. **Role: Contributing author.**
38. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, **Dent S**, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advance Breast Cancer: Final Results of NCIC CTG MA.31. *J Clin Oncol.* 2015 Mar 16. JCO.2014.56.9590 [Epub ahead of print]. Impact factor: 18.37. **Role: member trial subcommittee, national principal investigator, contributing author.**
39. Attard CL, Pepper AN, Brown ST, Thompson MF, Thuresson PO, Yunger S, **Dent S**, Paterson AH, Wells GA. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. *J Med Econ.* 2015 Mar;18(3):173-88. Impact Factor: 2.254. **Role: Contributing author.**
40. Enright K, Grunfeld E, Yun L, Moineddin R, Ghannam M, **Dent S**, Eisen A, Trudeau M, Kaizer L, Earle C, Krzyzanowska MK. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. *J Oncol Pract.* 2015 Mar;11(2):126-32. Impact Factor: Not Available. **Role: Contributing author.**
41. Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, Kondejewski J, Ayoub JP, Califaretti N, Rayson D, **Dent SF**. Novel agents and associated toxicities of inhibitors of the PI3K-Akt mTOR pathway for the treatment of breast cancer. *Curr Oncol.* 2015 Feb;22(1):33-48. Impact Factor: 1.785. **Role: Senior responsible author.**

2014

42. Sulpher J, Dattilo F, **Dent S**, Turek M, Reaume MN, Johnson C. Acute cardiogenic shock induced by infusional 5-Fluorouracil. *Case Rep Oncol Med.* 2014;2014:819396. Impact Factor: Not available. **Role: Senior responsible author.**
43. Johnson C, **Dent S**, Sulpher J, Hopkins S, Graham N, Law A, Stadnick E, Turek M. Anthracycline induced cardiomyopathy: favourable response to medical therapy in spite of remote anthracycline exposure. *Current Issues in Cardiac Rehabilitation and Prevention (CV Edge).* May 2014, page 5. Impact Factor: Not available **Role: Contributing author.**
44. Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, **Dent SF**, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. *World J Clin Oncol.* 2014 Dec 10;5(5):1088-96. Impact factor not available **Role: Contributing author.**
45. Zhu X, **Dent S**, Paquet L, Zhang T, Graham N, Song X. Factors influencing oncotype DX use in the management of early breast cancer: a single centre experience. *Eur J Cancer.* 2014 Oct;50(15):2544-9. Impact Factor: 4.819. **Role: Co-investigator.**

46. Addison CL, Bouganim N, Hilton J, Vandermeer L, **Dent S**, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. *Breast Cancer Res Treat.* 2014 Apr;144(3):615-24. Impact Factor: 4.198. **Role: Co-investigator.**
47. Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, **Dent S**, Gertler S, Bouganim N, Vandermeer L, Clemons M. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. *Oncologist.* 2014 Feb; 19(2):127-34. Impact Factor: 4.540. **Role: Co-investigator.**
48. Sulpher J, Dent R, **Dent S**. Neoadjuvant chemotherapy in breast cancer: what questions remain? *Curr Opin Support Palliat Care.* 2014 Mar;8(1):59-63. Impact Factor: Not available. **Role: Senior responsible author.**
49. Sulpher J, Johnson C, Turek M, Law A, Stadnick E, Hopkins S, Graham N, **Dent SF**. Ottawa Cardiac Oncology Programs wins 2013 Cancer Quality Council of Ontario Innovation Award. *Curr Oncol.* 2014 Jun;21(3):150. Impact Factor: 1.785. **Role: Senior responsible author.**
50. Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, **Dent S**, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. *Oncol Lett.* 2014 Mar;7(3):866-870. Impact Factor: 0.237. **Role: Contributing author.**

2013

51. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, **Dent SF**, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. *Breast Cancer Res Treat.* 2013 Nov;142(1):101-7. Impact Factor: 4.469. **Role: Co-investigator.**
52. **Dent SF**, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. *Invest New Drugs.* 2013 Dec;31(6):1522-9. Impact Factor: 3.498. **Role: Principal Investigator and first author.**
53. Rushton M, Kwong A, Visram H, Graham N, Petreich W, **Dent S**. Treatment outcomes for early stage male breast cancer: a single-centre retrospective case-control study. *Curr Oncol.* 2014 Jun;21(3):e400-7. Impact Factor: 1.785. **Role: Senior responsible author. Awarded PSI Research Award.**
54. **Dent S**, Oyan B, Honig A, Mano M, Howell S. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. *Cancer Treat Rev.* 2013 Oct;39(6):622-31. Impact Factor: 6.024. **Role: First author.**
55. Danitsaris G, Bouganim N, Milano C, Vandermeer L, **Dent S**, Wheatley-Price P, Laport J, Oxborough KA, Clemons M. Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. *J Support Oncol.* 2013 Mar;11(1):14-21. Impact Factor: Still Computing **Role: Contributing author.**
56. **Dent S**, Fraser J, Graham N, Campbell M, Hopkins S, Dranitsaris G. Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre. *Curr Oncol.* 2013 Feb;20(1):24-9. Impact Factor: 1.785. **Role: First author.**
57. Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, **Dent S**. The impact of endocrine therapy on sexual dysfunction in post-menopausal women with early stage breast cancer: encouraging results from a prospective study. *Breast Cancer Res Treat.* 2013 Aug;141(1):111-7. Impact Factor: 4.469. **Role: Senior responsible author.**

2012

58. Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Gobdout L, **Dent S**, Wheatley-Price P, Milano C, Clemons M. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. *Curr Oncol.* 2012 Dec;19(6):e414-21. Impact Factor: 1.785. **Role: Contributing author.**
59. **Dent S**, Hopkins S, Graham N, Johnson C, Law A, Campbell M, Crawley F, Allen K, Turek M. The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy:

An Observational Study. *Cardiol Res Pract.* 2012; 2012:135819. Impact Factor: Still Computing. **Role: First author.**

60. Daneshmand M, Hanson JE, Nabavi M, Hilton JF, Vandermeer L, Kanji F, **Dent SF**, Clemons M, Lorimer IA. Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. *ISRN Oncol.* 2012; 2012:492578. Impact Factor: Still Computing. **Role: Co-investigator.**
61. Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Dent S, Mirsky D, Chasen M, Caudrelier JM, Clemons M. Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma. *Curr Oncol.* 2012 Aug;19(4):e270-9. Impact Factor: 1.785. **Role: Contributing author.**
62. Zhu X, Bouganim N, Vandermeer L, **Dent SF**, Dranitsaris G, Clemons MJ. Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy - single-centre experience. *Curr Oncol* 2012 Aug;19(4):e239-e243. Impact Factor: 1.785. **Role: Co-investigator.**

2011

63. Dent SF and Graham NA. First Annual Cardiac Oncology Network Conference. *Curr Oncol.* 2011 Dec;18(6):295-300. Impact Factor: 1.785. **Role: First author.**
64. Grunfield E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, Joy AA, Provencher L, Rayson D, Rheaume DE, Porter GA, Paszat LF, Pritchard KI, Robidoux A, Smith S, Sussman J, **Dent S**, Sisler J, Wiernikowski J, Levine MN. Evaluating survivorship care plans: results of a randomized clinical trial in breast cancer patients. *J Clin Oncol.* 2011 Dec 20;29(36):4755-4762. Impact Factor: 18.038. **Role: Co-investigator.**
65. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, **Dent SF**, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollack MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in post-menopausal women: NCIC CTG MA.14. *J Clin Oncol.* 2011 Oct 10;29(29):3869-76. Impact Factor: 18.038. **Role: Local principal investigator and contributing author.**
66. Madarnas Y, **Dent SF**, Husain SF, Robinson A, Alkhayat S, Hopman WM, Verreault JL, Vanderburg T. Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. *Curr Oncol.* 2011 Jun;18(3):119-25. Impact Factor: 1.785. **Role: Co-investigator.**
67. **Dent SF**, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. *Breast Cancer Res Treat.* 2011 Apr;126(2):295-310. Impact Factor: 4.469. **Role: First author.**
68. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, Done SJ, Gianfelice D, Kanji F, **Dent S**, Barth D, Bouganim N, Al-Najjar A, Clemons M. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. *Breast Cancer Res Treat.* 2011 Oct;129(3):761-5. Impact Factor: 4.469. **Role: Co-investigator.**

2010

69. Visram H, Kanji F, **Dent SF**. Endocrine therapy for male breast cancer: rates of toxicity and adherence. *Curr Oncol.* 2010 Oct;17(5):17-21. Impact Factor: 1.785. **Role: Senior responsible author.**
70. Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, **Dent S**, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D. Optimizing the management of HER2-positive early breast cancer: the clinical reality. *Curr Oncol.* 2010 Aug;17(4):20-33. Impact Factor: 1.785. **Role: Contributing author.**
71. Wong NS, Buckman RA, Clemons M, Verma S, **Dent S**, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth receptor levels as markers of response. *J Clin Oncol.* 2010 Feb 10;28(5):723-30. Impact Factor: 18.038. **Role: local principal investigator and contributing author.**

72. **Dent SF**, Gertler S, Verma S, Segal R, Young V, Goel R, Keller O, Canil C, Iscoe N. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2010 Feb;65(3):557-61. Impact Factor: 2.795. **Role: First author.**
73. Taylor SK, Chia S, **Dent S**, Clemons M, Agulnik M, Greci P, Wang L, Oza AM, Ivy P, Pritchard KI, Leigh NB. A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium. *Oncologist*. 2010;15(8):810-8. Impact Factor: 3.91. **Role: Local principal investigator and contributing author.**

2009

74. Freedman O, Amir E, Dranitsaris G, Napolskikh J, Kumar R, Fralick M, Chia S, Petrella T, **Dent S**, Tonkin K, Ahmad I, Rayson D, Clemons M. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. *Breast Cancer Res Treat*. 2009 Nov;118(2):377-83. Impact Factor: 4.469. **Role: Contributing author.**
75. **Dent SF**. The role of VEGF in triple-negative breast cancer: where do we go from here? *Ann Oncol*. 2009 Oct;20(10):1615-7. Impact Factor: 7.384. **Role: First author.**
76. Lemieux J, Clemons M, Provencher L, **Dent S**, Latreille J, Mackey J, Pritchard KI, Rayson D, Verma Sh, Verma S, Wang B, Chia S. The Role of Neoadjuvant HER2-Targeted Therapies in HER2-Overexpressing Breast Cancers. *Curr Oncol*. 2009 Sep;16(5):48-57. Impact Factor: 1.785. **Role: Contributing author.**
77. **Dent S**, Verma Sh, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K. The role of HER2-targeted therapies in women with HER2 over expressing metastatic breast cancer. *Curr Oncol*. 2009 Aug;16(4):25-35. Impact Factor: 1.785. **Role: First author.**
78. Chia S, **Dent S**, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. *Clin Cancer Res*. 2009 Jan 15;15(2):708-13. Impact Factor: 7.837. **Role: Local principal investigator and contributing author.**

2008

79. Verma S, **Dent S**, Chow BJ, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. *Cancer Treat Rev*. 2008 Aug;34(5):391-406. Impact Factor: 6.024. **Role: Contributing author.**
80. Grunfeld E, Urquhart R, Mykhalovskiy E, Folkes A, Johnston G, Burge FI, Earle CC, **Dent S**. Toward population-based indicators of quality end-of-life care: testing stakeholder agreement. *Cancer*. 2008 May 15;112(10):2301-8. Impact Factor: 5.201. **Role: Contributing author.**
81. **Dent S**, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systemic review. *Breast Cancer Res Treat*. 2008 Apr;108(3):319-31. Impact Factor: 4.469. **Role: First author.**
82. Saginur R, **Dent SF**, Schwartz L, Heslegrave R, Stacey S, Manzo J. The Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board. *J Clin Oncol*. 2008 Mar 20;26(9):1479-82. Impact Factor: 18.038. **Role: Contributing author.**
83. Leigh NB, **Dent S**, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. A Phase II study of perifosine in advanced or metastatic breast cancer. *Breast Cancer Res Treat*. 2008 Mar;108(1):87-92. Impact Factor: 4.469. **Role: Local principal investigator and contributing author.**
84. Mackey JR, Clemons M, Côté MA, Delgado D, **Dent S**, Paterson A, Provencher L, Sawyer MB, Verma S. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. *Curr Oncol*. 2008 Jan;15(1):24-35. Impact Factor: 1.785. **Role: Contributing author.**

2006

85. **Dent S**, Messersmith H, Trudeau M, and the Breast Cancer Disease Site Group. The Role of Gemcitabine in the Management of Metastatic Breast Cancer: A Clinical Practice Guideline. A quality initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario, 2006. Refer to www.cancercare.on.ca
86. Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, **Dent S**, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T: Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. *J Clin Oncol.* 2006 24(6):848-55.

2005

87. Bjarnason GA, Charpentier D, Wong R, Goel R, Douglas L, Walsh W, Matthews S, **Dent S**, Seymour L: Phase I study of tomudex and doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). *Invest New Drugs* 23:51-56, 2005.

2004

88. Reyno L, Seymour L, Tu D, **Dent S**, Gelmon K, Walley B, Pluzanski A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K: Phase III Study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. *J Clin Oncol* 22: 269-276, 2004.

2003

89. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, **Dent S**, Abu-Zahara H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I. Helping patients make informed choices. A randomised trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. *J National Cancer Inst.* April 2003;95(8):570-1

2001

90. **Dent S**, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. Application of a New Multinomial Phase II Stopping Rule Using Response and Early Progression. *J Clin Oncol* 19: 785-791, 2001.

2000

91. **Dent S**, Klassen D, Pater JL, Zee B, Whitehead M. Second Primary Malignancies Following the Treatment of Early Stage Ovarian Cancer: Update of a Study by the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). *Annals of Oncology*, 11: 65-68, 2000.

1999

92. Khoo K, Brandes L, Reyno L, Arnold A, **Dent S**, et al. Phase II Trial of N, N-Diethyl – 2 [4 – (phenylmethyl) phenoxy] ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. *Journal of Clinical Oncology*, Vol. 17 (11), 3431 – 3437, 1999.

1996

93. **Dent S**, Eisenhauer EA. Phase I Trial Design: Are New Methodologies Being Put Into Practice? National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) ; Queens University, Kingston, Canada. *Annals of Oncology*, 7: 561-566, 1996.
94. **Dent S**, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart DJ: PROMACE-MOPP and Intrathecal Chemotherapy for CNS Lymphoma, Ottawa Regional Cancer Centre, Ottawa, Ontario. *Journal of Neuro-Oncology* 28: 25-30, 1996.

Submitted/In Preparation

1. Michelino De Laurentiis,¹ Patrick Neven,² Guy Jerusalem,³ Thomas Bachelot,⁴ William Jacot,⁵ **Susan Dent**,⁶ Marco Colleoni,⁷ Aleix Prat,⁸ Miguel Martin,⁹ Alistair Ring,¹⁰ Paul Cottu,¹¹ Janice Lu,¹² Hamdy A. Azim,¹³ Katie Zhou,¹⁴ Jiwen Wu,¹⁴ Juan Pablo Zarate,¹⁴ Claudio Zamagni¹⁵
Ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population: preliminary safety results from ComPLEEment-1. Submitted to Breast Cancer Research and Treatment, September, 2018
2. Lenihan D, Barac A, Fradley M, Blaes A, Herrmann J, Porter C, Patel A, DeCara J, Lyon A, Hartlage G, Harrison E, Ganatra S, Moslehi J, Oliveira G, Parasher S, Turner R, Wsittles R, Curigliano G, Cardinale D, Krone R, Iakobishvili Z, Carver J, Douglas P, Armenian S, Ky B, **Dent S**. Management of Cardiac Disease in Cancer Patients throughout Oncologic Treatment: A Compendium of Recommendations for the Translational Researcher and Practitioners of Cardio-Oncology. Submitted September 2018 JAMA Cardiology.
3. Phillips W, Johnson C, Law A, Turek M, Small A, Inacio J, **Dent S**, Ruddy T, Beanlands R, Chow B, Small G. Clinical reporting of arterial calcium on chest CT studies in breast cancer patients referred to a cardio-oncology clinic. Submitted September 2018
- 4.
5. Robinson S, Ibrahim M, Stober C, Hilton J, Kos Z, Mazzarello S, Ramsey T, Fergusson D, Vandermeer L, Mallick R, Arnaout A, **Dent S**, Segal R, Sehdev S, Gertler S, Hutton B, Clemons M. Does integration of Magee scores into routine clinical practice affect whether oncologists order the Oncotype Dx test? Submitted January 2018, Journal of Oncology Practice
6. Klein R, Nadouir D, Osler E, Johnson C, **Dent S**, Dwivedi G. Systolic dysfunction can precede diastolic dysfunction in cancer patients receiving trastuzumab based therapy. Submitted January 2018 European Journal of Nuclear Medicine and Molecular Imaging.
7. Kappel, C. Johnson C., Rushton M. Aseyev O, Small G, Law A, Ivars J, and Dent S. Clinical Experience of patients referred to a multidisciplinary cardio-oncology clinic: An observational study. Submitted to Current Oncology September 2018
8. Shao Z, Ling-Ming T, Huang CS, Pang D, Yang Y, Li W, Liao N, Gneg C, Zhang Q, Xu B, Liu D, Kwong A, Yu M, Sun G, Bergh J, **Dent S**, Arhmani A, Borthwick G, Henot F, Minchwitz G, Jiang Z. Pertuzumab and trastuzumab as adjuvant treatment for patients with HER-2 positive early breast cancer: analysis of outcomes in Chinese patients in the randomized APhinity study. submitted to Annals of Oncology September 2018

Book Chapters

1. Khouri M, Klem I, Shenoy C, **Dent S**. Screening and Monitoring for Cardiotoxicity during Cancer Treatment. Chapter 3 pg. 43-80. Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease, Springer International Publishing, 2017
2. **Dent S**, Law A, Aseyev O, Ghosh N, Johnson C. Co-ordinating Cardio-Oncology Care. Chapter 15 pg. 221-236. Cardio-Oncology: Principles, Prevention and Management. Elsevier publications, 2017.
3. Barac A, O'Quinn R, **Dent S**, Aseyev O, Carver J. Cardio-Oncology Fellowship Programs. Chapter 23. pg 453-463. Clinical Cardio-Oncology, Elsevier publications, 2016.

Podcast

1. **Dent S**, Guideline-based eligibility, cancer events and non-cardiovascular mortality in the Framingham heart study by Pursani et.al. Podcast ID: JCO/2017/744151, May, 2017.

Workshops:

- 1) Chair: How to set up a cardio-oncology program: a case based how-to guide for health care providers involved in the cardiac care of cancer patients. Canadian Cardiovascular Society annual meeting, October 21, 2017 Vancouver, Canada.

Papers /Articles (Non-Peer Reviewed)

1. Rushton M and **Dent S**. Highlights from the San Antonio Breast Cancer Symposium 2017. *Oncology Exchange* Vol. 17, No.2 May 2018.
2. **Dent S** and Chia S. Highlights from San Antonio Breast Cancer Symposium 2016. *CARE Perspectives*, 2016.
3. **Dent S**, How to reduce harm to the heart while treating cancer: sub-speciality of cardio-oncology expands rapidly. *The Ottawa Hospital Journal*, Vol. 19. No. 3 March 2016
4. **Dent S**, Aseyev O, Lenihan D. On-going research developments in cardio-oncology. *OncoReview*, March 2016.
5. **Dent S**, Febrile Neutropenia – What can we learn? *Oncology Exchange* Vol 15, No. 1 February 2016.
6. Sulpher J, Graham N, Johnson C, Turek M, Law A, Stadnick E, Wentzell J, **Dent S**. Cardiac Oncology: improving cardiac safety, advancing cancer care. *Cancer Care Report Card*, Cancer Advocacy Coalition of Canada. April 7, 2015.
7. Sulpher J and **Dent S**. Advances in the management of metastatic HER2-positive and triple-negative breast cancer. *Oncology Exchange* 2014; 13:26-29.
8. Segal R and **Dent S**. “Screening Mammography– What does the future hold”. *Canadian Medical Association Journal: Editorial Letter*. January 5, 2012.
9. **Dent SF**, Yurichuk S. Should clinical trials be considered part of “Standard of Care”? *Cancer Care Report Card*, Cancer Advocacy Coalition of Canada 2011 Apr; 13:23-29.
10. **Dent S**. Bevacizumab with three dosages of nab-paclitaxel. *Oncology Exchange* 2009; 8(4).
11. **Dent S**. Bevacizumab in metastatic breast cancer. *Oncology Exchange* 2009; 8(3):20-21.
12. **Dent S**. A Canadian Clinical Perspective on Antiangiogenic Therapy for HER2-Negative Metastatic Breast Cancer. *PeerView in Review*, 2009.
13. Lorimer I, **Dent S**. The changing world of breast cancer treatment: New drugs create new challenges. *Challenge*, 2009.
14. **Dent S**. Bone effects of endocrine therapy; ATAC: long-term results of anastrozole on BMD. Highlights from the 44th ASCO Annual Meeting. *Innovations* 2008; 6(2).
15. **Dent S**. Hormonal therapy and sequelae. Highlights from the 30th annual San Antonio Breast Cancer Symposium. *Innovations* 2008; 6(1).
16. **Dent S**. Winning the war on cancer. *Reader’s Digest*, 49-54, March 2008.
17. **Dent S**, *Hormonal therapy and sequelae*. Highlights from the 30th annual San Antonio Breast Cancer Symposium. *Innovations*, 6(1), 2008.
18. Claudia Cornwall with interview input from **Dent S**: *Winning the war on cancer*. *Reader’s Digest*, 49-54, March 2008.
19. **Dent S**, Catalin Mihalcioiu: New advances in treating breast cancer: An update from ASCO focusing on the role of taxanes in chemotherapy. *Oncology Exchange*, Vol 6, No 3, August 2007

20. **Dent S**, Xinni Song, The role of taxanes in the treatment of breast cancer: New approaches to tailoring therapy and minimizing toxicities. *Oncology Exchange*, Vol 6, No 1, February 2007.
21. **Dent S**. Beyond HER2 and ER: Identification of novel molecular targets in breast cancer represents a step forward. *Innovations in Breast Cancer*, vol 4, no 3, 2006.
22. **Dent S**. Review of 42nd Annual Meeting of ASCO, June 2006”, Vol 5, No. 3, Atlanta, Georgia. *Oncology Exchange*, July 2006
23. **Dent S**. “Breast Cancer Chemotherapy” Review of 27th San Antonio Breast Cancer Symposium” *Oncology Exchange* Vol 4, No. 1, February 2005.
24. **Dent S**. Highlights from the 27th San Antonio Breast Cancer Symposium. A review of the recent breast cancer trial data on aromatase inhibitors vs tamoxifen in postmenopausal women, evolving role of taxanes in early breast cancer and partial breast irradiation in select patients. *Innovations in Breast Cancer*, vol 3, no 1, 2005.
25. **Dent S**. Commentator: *Innovations in Breast Cancer Care*, Clinical applications for Canadian oncologists, vol 2, no 3, 2004.
26. **Dent S**, Commentator: Review of the 25th Annual San Antonio Breast Cancer Symposium. The ATAC trial in postmenopausal women with early breast cancer – update efficacy results based on a median follow-up of 47 months. *Oncology Exchange*, Vol 2, No. 1 February 2003
27. **Dent S**. Highlights from the 8th International Nottingham Breast Cancer Conference and the 12th Annual European Cancer Conference. A review of recent breast cancer trial data on adjuvant treatment, aromatase inhibitors, first-line therapy for Her2-positive disease and treatment of metastatic disease. *Innovations in Breast Cancer Care* Vol. 1, no.2, 2003.
28. **Dent S**. “Highlights from the 25th Annual San Antonio Breast Cancer Symposium held in December 2002”. In *Stride*, Spring 2003.
29. **Dent S**. *Innovations in Breast Cancer Care: Clinical Applications for Canadian Oncologists*. Notable reports from Nottingham and ECCO – Relevant recent trial results with commentary. Tamoxifen (S) followed by an aromatase inhibitor (AI) in early breast cancer. A pooled analysis of two consecutive trials (Abstract 0-37) vol. 1 no 2, 2003.
30. **Dent S**. Focusing on highlights from the 25th Annual San Antonio Breast Cancer Symposium, held in December 2002. In *Stride: Breast Cancer and the Road to Recovery*. Pankhurst Publ. Spring 2003.
31. **Dent S**. *Advances in the Management of Metastatic Breast Cancer*. *Oncology Update*. A Series for Canadian Oncologists and Hematologists, May 1998.

Presentation of Papers at meetings and Symposia (i.e Abstracts)

Local

1. Aseyev O, Sulpher J, Crowley F, Botros J, Nadine Graham, Christopher Johnson, **Dent S** Assessment of subclinical treatment-induced cardiotoxicity using left ventricular ejection function in breast cancer patients during trastuzumab treatment, OHRI Research Day, October, 2016. **Poster presentation.**
2. J. Sulpher¹, K.E. Boczar², C. Johnson^{1,2}, I. Burwash², M. Turek^{1,2}, I. Al-Harbi², O.Aseyev¹, G. Dwivedi², and **S. Dent** Cardiac safety of anthracycline-based chemotherapy in breast cancer patients: Is right heart function adversely affected?. The Ottawa Hospital Annual Patient Safety Day, October, 2015
3. Clemons M, Mazzarello S, Hilton J, Stewart D, Arnaout A, Vandermeer L, Hutton B, Graham I, **Dent S**, Grimshaw J, Fergusson F. A randomized study to determine the feasibility of using an integrated consent model to compare two standard of care regimens for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia. Annual Patient Safety Day, The Ottawa Hospital, October 2015
4. Rushton M, Crowley F, Graham N, Johnson C, Sulpher J, **Dent S**. Validation of Heart Failure Prediction Tool in

Cardio-oncology Breast Cancer Population [abstract]. In: 28th Annual University of Ottawa Heart Institute Research Day, Ottawa, Ontario – May 5, 2015. **Oral Presentation.**

5. Law W, Crawley F, Rushton M, Graham N, Johnson C, Sulpher J, **Dent S.** Application of Framingham Risk Score in Human Epidermal Growth Factor Receptor 2 positive (HER2+) breast cancer patients referred to a cardio-oncology clinic [abstract]. In: 3rd Annual Ottawa Heart Research Conference, Ottawa, Ontario – April 24, 2015. **Poster Presentation.**
6. Law W, Crawley F, Rushton M, Graham N, Johnson C, Sulpher J, **Dent S.** Application of Framingham Risk Score in Human Epidermal Growth Factor Receptor 2 positive (HER2+) breast cancer patients referred to a cardio-oncology clinic [abstract]. In: University of Ottawa Research Opportunity Program Day, Ottawa, Ontario – April 2, 2015. **Poster Presentation.**
7. Sulpher J, Lenihan D, Johnson C, Turek M, Law A, Stadnick E, Dattilo F, Graham N, **Dent S.** An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapies [abstract]. In: The Ottawa Hospital Department of Medicine Resident Research Day, Ottawa, Ontario – May 4, 2014.
8. Sulpher JA, Dattilo F, Law A, Dranitsaris G, Crawley F, Graham N, **Dent S,** Johnson C. Development of a Predictive Model to Estimate Cardiotoxic Risk Associated with Anthracyclines and Trastuzumab [abstract]. In: TOH 9th Annual Patient Safety Day, Ottawa, Ontario - October 29, 2013. **Poster presentation.**
9. Sulpher JA, Dattilo F, Johnson C, Law A, Turek M, Stadnick E, Hopkins S, Campbell M, Crawley F, Graham N, **Dent S.** Clinical Outcomes of patients referred to a cardiac oncology clinic at a tertiary care centre [abstract]. In: The Ottawa Hospital Department of Medicine Residents' Research Day, Ottawa, Ontario - June 5, 2013. **Poster presentation.**
10. Rushton M, Kwong A, Visram H, Graham N, Balchin K, Petrich W, **Dent S.** Treatment outcomes for early stage male breast cancer: a single centre retrospective case-control study [abstract]. In: University of Ottawa Resident Research Day, Ottawa, Ontario - June 5, 2013, **Oral Presentation.**
11. Sulpher JA, Dattilo F, Johnson C, Law A, Turek M, Stadnick E, Hopkins S, Campbell M, Crawley F, Graham N, **Dent S.** Clinical Outcomes of patients referred to a cardiac oncology clinic at a tertiary care centre [abstract]. In: 3rd Annual Canadian Cardiac Oncology Network Conference, Ottawa, Ontario - June 20-21, 2013. **Poster presentation.**
12. Sulpher J, Dattilo F, Law A, Dranitsaris G, Crawley F, Graham N, **Dent S,** Johnson C. Development of a Predictive Model to Estimate Cardiotoxic Risk Associated with Anthracyclines and Trastuzumab [abstract]. In: TOH 9th Annual Patient Safety Day, Ottawa, ON - October 29th, 2013. **Poster presentation.**
13. Kwong A, Visram H, Graham N, **Dent S.** Treatment Outcomes for Early Stage Male Breast Cancer: A Single Centre Retrospective Case-Control Study [abstract]. In: Resident Research Day, University of Ottawa, Department of Medicine, Ottawa, Ontario - May 23, 2012. **Oral presentation.**
14. Zhu X, Graham N, Paquet L, **Dent S,** Song X. Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, HER2/neu Negative Breast Cancer [abstract]. In: Resident Research Day, University of Ottawa, Department of Medicine, Ottawa, Ontario - May 23, 2012. **Best oral presentation award.**
15. Pourdjabbar A, Turek M, **Dent S.** Cardiac-toxicity associated with Sunitinib in patients with metastatic renal cell carcinoma and metastatic gastrointestinal stromal tumor [abstract]. In: Resident Research Day, University of Ottawa, Department of Medicine, Ottawa, Ontario - May 25, 2011. **Poster presentation.**
16. Zhu X, Bouganim N, Vandermeer L, **Dent S,** Dranitsaris D and Clemons M. G-CSF (filgrastim and pegfilgrastim) Utilization and Delivery in Breast Cancer Patients Receiving Neo/Adjuvant Chemotherapy [abstract]. In: Resident Research Day, University of Ottawa, Department of Medicine, Ottawa, Ontario - May 25, 2011. **Poster presentation.**

National

17. O. Aseyev, M. Turek, C. Johnson, F. Crowley, **S.Dent** Age is a factor for referral of women with left ventricular dysfunction during trastuzumab-based treatment for HER2-positive breast cancer: single-center retrospective data analysis, Womens Heart Health Summit, Ottawa, April 2016. **Poster presentation.**

18. **S. Dent**, O. Aseyev, C. Johnson, M. Turek, N. Ghosh Establishment of a comprehensive cardio-oncology and a cardiovascular survivorship program: continuum of care, Poster. Cancer Care Ontario, April, 2016 Toronto, Ontario. **Poster presentation.**
19. Olexiy Aseyev, Christopher Johnson, Michele Turek, Jeffrey Sulpher, Angeline Law, **Susan Dent** Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patient., Canadian Association of Medical Oncologists (CAMO), Toronto, Ontario, April 2016. **Oral presentation.**
20. Clemons M, Catley C, vanWalraven C, Arnaout A, Booth CM, McInnes M, Fergusson D, **Dent S**, Simos D. Imaging for distant metastases in women with early stage breast cancer: A population-based, cohort study [abstract]. In: Canadian Cancer Research Conference, Montreal, Quebec – November 8-10, 2015. **Poster presentation.**
21. Rushton M, Crawley F, Graham N, Johnson C, Sulpher J, **Dent S**. Validation of Heart Failure Prediction Tool in Cardio-oncology Breast Cancer Population [abstract]. In: Canadian Association of Medical Oncologists Annual Scientific Meeting, Toronto, Ontario – April 30, 2015. **Oral Presentation.**
22. Clemons M, Arnaout A, Hilton J, Graham I, Stewart D, **Dent S**, Hutton B, Ferguson B, Grimshaw J, Mazzarello S. RETHinking Clinical Trials (REACT) in Ontario: Evaluating the Feasibility of using an Integrated Consent Model to Compare Standard of Care Treatments [abstract]. In: Ontario Institute for Cancer Research Scientific Meeting, Toronto, Ontario – March 12-13, 2015. **Poster presentation.**
23. Attard CL, Pepper AN, Brown ST, Thompson MR, Thuresson PO, Yunger S, **Dent S**, Paterson AH, Wells GA: Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory or early HER2+ breast cancer in Canada [abstract]. In: Canadian Association for Population Therapeutics (CAPT) Annual meeting 2014, Toronto, Ontario – November 2-4, 2014. **Poster presentation.**
24. Sulpher JA, Dattilo F, Law A, Dranitsaris G, Crawley F, Graham N, **Dent S**, Johnson C. Development of a Predictive Model to Estimate Cardiotoxic Risk Associated with Anthracyclines and Trastuzumab [abstract]. In: 4th Annual Canadian Cardiac Oncology Network Conference, Ottawa, Ontario - May 8-9 2014. **Poster presentation.**
25. Sulpher J, Lenihan D, Johnson C, Turek M, Law A, Stadnick E, Dattilo F, Graham N, **Dent S**. An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapy [abstract]. In: Canadian Association of Medical Oncologists Annual Scientific Meeting, Toronto, Ontario - May 1, 2014. J Clin Oncol. 32:5s, 2014, Abstr 6629. **Poster presentation.**
26. Rushton M, Kwong A, Visram H, Graham N, Balchin K, Petrcich W, **Dent S**. Treatment outcomes for early stage male breast cancer: a single centre retrospective case-control study [abstract]. In: University of Ottawa Resident Research Day, Ottawa, Ontario - June 5, 2013, **Oral Presentation.**
27. Sulpher J, Johnson C, Law A, Hopkins S, Graham N, Crawley F, Campbell M, Turek M, **Dent S**. Clinical outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre [abstract]. In: University of Ottawa Resident Research Day, Ottawa, Ontario - June 5, 2013, **Poster presentation.**
28. Rushton M, Kwong A, Visram H, Graham N, Balchin K, Petrcich W, **Dent S**. Treatment outcomes for early stage male breast cancer: a single centre retrospective case-control study [abstract]. In: 2013 CAMO Annual Scientific Meeting, Toronto, Ontario - April 25, 2013, **Oral Presentation.**
29. Sulpher JA, Dattilo F, Johnson C, Law C, Turek M, Stadnick E, Hopkins S, Campbell M, Crawley F, Graham N, **Dent S**. Clinical Outcomes of patients referred to a cardiac oncology clinic at a tertiary care centre [abstract]. In: 2013 CAMO Annual Scientific Meeting, Toronto, Ontario - April 25, 2013. **Poster presentation.**
30. Sulpher J, Johnson C, Law A, Hopkins S, Graham N, Crawley F, Campbell M, Turek M, **Dent S**. Clinical outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre [abstract]. In: 2013 CAMO Annual Scientific Meeting, Toronto, Ontario - April 25, 2013, **Poster presentation.**
31. O'Brien J, Grunfield E, Sussman J, Porter G, Paszat L, **Dent S**, Hammond M. The use of a Survivorship Care Plan in the re-integration of breast cancer patients following discharge from specialist care: views of family physicians [abstract]. In: Family Medicine Forum, Toronto, Ontario - November 15-17, 2012. **Poster presentation.**

32. Zhu X, Graham N, Paquet L, **Dent S**, Song X. Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, HER2/neu Negative Breast Cancer [abstract]. In: 2012 CAMO Annual Scientific Meeting, Toronto, Ontario - April 26, 2012. Abstract nbr 1864. **Poster presentation.**
33. Bouganim N, Dranitsaris G, Vandermeer L, Hopkins S, **Dent S**, Wheatley-Price P, Young C, Clemons MJ. Prospective validation of risk prediction models for acute and delayed chemotherapy induced nausea and vomiting (CINV) [abstract]. In: 2011 CAMO Annual Scientific Meeting, Toronto, Ontario - April 28-30, 2011. **Poster discussion.**
34. Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Asmis T, Graham N, **Dent S**. How common is sexual dysfunction among women with early stage breast cancer? [abstract]. In: 2011 CAMO Annual Scientific Meeting, Toronto, Ontario - April 28-30, 2011. **Poster presentation.**
35. Zhu X, Bouganim N, Vandermeer L, **Dent S**, Dranitsaris D and Clemons M. G-CSF (filgrastim and pegfilgrastim) Utilization and Delivery in Breast Cancer Patients Receiving Neo/Adjuvant Chemotherapy [abstract]. In: 2011 CAMO Annual Scientific Meeting, Toronto, Ontario - April 28-30, 2011. **Poster presentation.**
36. Paquet L, Frechette D, **Dent S**, Song X, Verma S. The Impact of Menopausal Symptoms on Quality of Life Among Post-Menopausal Early Breast Cancer Survivors: The Role of Personality [abstract]. In: Canadian Association of Psychosocial Oncology Annual Conference, Quebec City, Quebec - May 25-29, 2010. **Poster presentation.**
37. Taylor S, Chia S, **Dent S**, Clemons M, Greni P, Wang L, Oza A, Ivy P, Pritchard K, Leighl N. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I. A trial of the Princess Margaret Hospital Phase II Consortium [abstract]. In: 2009 CAMO Annual Scientific Meeting, Toronto, Ontario - April 29, 2009. **Poster presentation**
38. Fitzgerald B, Brackstone M, Dent R, **Dent S**, Azzi J, Bentall T, Chaisson K, Dale D, Gardner S, Tahir M, Tamayo C, Clemons M. Establishing a provincial prospective database to track outcomes and drive research in women diagnosed with locally advanced breast cancer [abstract]. In: NCIC Annual Meeting, Toronto, Ontario - November 15-17, 2007. **Poster presentation.**
39. Grunfeld E, Cicchelli L, Mykhalovskiy E, **Dent S**, Zitzelsberger L, Johnston G, Burge F, Earle C, Paszat L. Quality indicators for end-of-life breast cancer care: Is there agreement between stakeholder groups in two provinces [abstract]. In: 16th International Congress on the Care of the Terminally Ill, Montreal, Quebec - Sep 26-29, 2006. **Oral Presentation.**
40. **Dent S**, DiValentin T, Vandermeer L, Spaans J, Verma S. Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center [abstract]. In: Canadian Winter Oncology Conference; March 2-5, 2006; Kamloops, British Columbia. Breast Cancer Res Treat 100 [suppl 1; abstr 4057].
41. Wong N, Buckman R, Clemons M, Verma S, **Dent S**, Trudeau M, Roche K, Kerbel R, DeBoer G, Sutherland D, Pritchard K. Metronomic daily dalteparin, cyclophamide and prednisone and bi-weekly methotrexate as therapy for metastatic breast cancer [abstract]. In: CAMO Meeting; Mar 31, 2005; Montreal, Quebec. Poster presentation.
42. Grunfeld E, Levine M, Julian J, Coyle D, **Dent S**, Ginsburg D, Verma S, Sawka C, Wood M, Mirsky D: A Randomized Trial of Follow-up Strategies for Breast Cancer: acceptability of the study to patients, family physicians and specialists [abstract]. In: Canadian Breast Cancer Research Initiative Conference; May 3-5, 2001; Quebec City. Oral presentation.
43. Zaza C, Sellick S, Reyno L, Whelan T, **Dent S**. Cancer Pain and Coping: Examination of a Chronic Non-Malignant Pain Classification System in Patients with Chronic Cancer Related Pain [abstract]. In: Canadian Association of Psychosocial Oncology (CAPO) Annual Meeting and Conference; May 3-6, 1998; Thunder Bay, Ontario.
44. **Dent S**, Zee B, Dancy J, Melnychuck D, Eisenhauer E, Steward W, Lu F. Design of phase II clinical trials - stopping rule using response and early-progression [abstract]. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Ann.Oncol. 7(Suppl 1), 134, 1996.
45. **Dent S**, Bociek G. Prophylactic Anticonvulsants for cancer patients with newly diagnosed brain metastases. National Cancer of Canada Clinical Trials Group, Queen's University, Kingston, Ontario [abstract]. In: Resident's Research Day, Department of Medicine University of Ottawa; May, 1995; Ottawa, Ontario. Best Oral Presentation.

International

46. O'Shaughnessy J, Alba A, Bardia A, **Dent S**, Dieras V, Hortobagyi G, Seock-Ah K, Montermurro F, Untch M, Yardley D, Chakravarty A, Germa C, Miller M, Slamon D. EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor –positive (HR +), human epidermal growth factor receptor negative (HER2-), intermediate-risk, early breast cancer (EBC). SABCS, 2017. **Poster presentation.**
47. **Dent S**, Califaretti N, Doyle C, Ferrario C, Chouinard E, Kulkarni S, Roy J, Perri S, Chia S. Treat ER+ight Canadian prospective observational study in HR + advanced breast cancer: 2nd interim analysis. SABCS, December 2017. **Poster presentation.**
48. Olexiy Aseyev, MD, PhD, Lisa Simmonds, Maddie Gertler, **Susan Dent**, MD, and Shailendra Verma, MD Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment, SABCS, December 2016. **Poster presentation.**
49. Olexiy Aseyev, Christopher Johnson, Michele Turek, Jeffrey Sulpher, Angeline Law, **Susan Dent**. Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab related cardiotoxicity in breast cancer patients. SABCS, December 2016. **Poster presentation**
50. Olexiy Aseyev¹ MD, PhD; Kathryn Ascah², MD; Girish Dwivedi², PhD, MD; Glenn Wells², PhD; John Hilton¹, MD; Jeffrey Sulpher¹, MD; Terrence Ruddy², MD; **Susan Dent**¹, MD Detection of apoptosis and relationship to ventricular function in patients with early stage breast cancer receiving anthracycline-based chemotherapy. Global Cardio-oncology Symposium (GCOS), Nashville, Tennessee, September 2016. **Poster presentation.**
51. **Susan F. Dent**, Olexiy Aseyev, Mark Levine, Kathleen Pritchard, Wendy Parulekar, Bingshu E. Chen, Patti O'Brien, Margot Burnell, Lois Shepherd Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The NCIC CTG (CCTG) MA.21 experience. ASCO Chicago, J Clin Oncol 34, 2016 (suppl: abstr 1016) **Poster discussion**
52. Olexiy Aseyev¹, Christopher Johnson, Michele Turek, Jeffrey Sulpher, Angeline Law, **Susan Dent**. Trastuzumab-related cardiotoxicity in breast cancer patients with obesity, dyslipidemia, and diabetes. ASCO, Chicago, J Clin Oncol 34 (suppl; abstr e 12503)
53. Califaretti N, Bouganim N, **Dent S**, et al, Treat ER+ight: Treatment of Canadian postmenopausal women with ER + HER2 – advanced breast cancer in the real-world setting with hormone therapy +/- targeted therapy. ASCO, Chicago, J Clin Oncol 34, 2016 (suppl: abstr TPS614)
54. O. Aseyev, **S. Dent**, C. Johnson, M. Turek, N. Ghosh Continuum of care: establishment of a comprehensive cardio-oncology program, ASCO survivorship symposium. San Francisco, January 2016. **Poster presentation.**
55. **Susan Dent**, Sean Virani, Bonnie Ky, Jose Lopez-Sendon, Teresa López Fernández, Olexiy Aseyev, Jeffrey Sulpher, Christopher Johnson, Daniel Lenihan The development of an international cardiooncology registry: a work in progress, Global Cardio-Oncology Summit(GCOS), Nashville, Tennessee, October 2015. **Poster Presentation**
56. Olexiy Aseyev, Jeffrey Sulpher, Freya Crowley, Joyes Botros, Nadine Graham, Christopher Johnson, **Susan Dent** Assessment of subclinical treatment-induced cardiotoxicity using left ventricular ejection function in breast cancer patients during trastuzumab treatment, Global Cardio-Oncology Symposium (GCOS), Nashville, Tennessee, October, 2015 **Poster Presentation**
57. Agarwal P, Chunze Li, Gibiansky L, **Dent S**, Goncalves A, Yi J, Strasak A, LoRusso P, Girish S. Phase I study of trastuzumab emtansine in HER2-positive metastatic breast cancer (MBC) in patients with normal or reduced hepatic ASCPT conference, 2016 **Poster presentation**
58. Rushton M, Crawley F, Law W, Graham N, Johnson C, Sulpher J, **Dent S**. Validation of heart failure prediction tool in cardio-oncology breast cancer population [abstract]. In: 2015 ASCO Annual Meeting, Chicago, Illinois – May 29-June 2, 2015. **Poster presentation.**
59. Song X, **Dent SF**, Verma S, Clemons MJ, Graham NA, Bedard M, Paquet L. Impact of personality traits on predictors of adherence to endocrine therapy [abstract]. In: 2015 ASCO Annual Meeting, Chicago, Illinois – May 29-June 2, 2015. **Poster presentation.**

60. Li C, Agarwal P, **Dent S**, Goncalves A, Yi JH, Strasak A, Green M, Girish S, LoRusso P. Phase I study of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function [abstract]. In: 37th Annual SABCS, San Antonio, Texas – December 9-13, 2014. **Poster presentation**.
61. Sulpher J, Dattilo F, Law A, Dranitsaris G, Crawley F, Kovacs M, Graham N, **Dent S**. Development of a cardiac toxicity predictive tool for HER2 (+) breast cancer patients receiving trastuzumab [abstract]. In: 37th Annual SABCS, San Antonio, Texas – December 13, 2014. **Poster presentation P6-09-03**.
62. Rushton M, Crawley F, Sulpher J, **Dent S**. Cardiac Toxicity in Breast Cancer Patients: A single centre retrospective review [abstract]. In: 37th Annual SABCS, San Antonio, Texas – December 11, 2014. **Poster presentation P3-12-1**
63. Emmenegger U, Sousa BA, Hoang VC, Chow A, Clemons M, **Dent S**, Wong NS, Kerbel R, Trudeau ME, Slingerland J, Eisen A, Ebos JM, Chan K, Gardner S, Pritchard K. Generation of a plasma microRNA signature predicting response to metronomic chemotherapy for advanced breast cancer [abstract]. In: ESMO 2014, Madrid, Spain – September 24-30, 2014. **Poster presentation**.
64. Sulpher J, Andrew P, Majeed H, Johnson C, Graham N, **Dent S**. Data-driven timing of optimal LVEF assessment in breast cancer patients exposed to trastuzumab [abstract]. In: ESMO 2014, Madrid, Spain – September 24-30, 2014. Abstract #6998. **Poster presentation**.
65. **Dent SF**, Sulpher JA, Johnson C, Turek M, Graham NA, Dattilo F, Lehnihan J. An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapies [abstract]. In: 2014 ASCO Annual Meeting, Chicago, Illinois, May 30-June 3, 2014. J Clin Oncol 32:5s, 2014, Abstr 6629. **Poster presentation**.
66. Zhu X, **Dent SF**, Paquet L, Zhang T, Graham NA, Song X. Use of oncotype DX in systemic treatment decision making for patients with stage 1 and II, hormone receptor positive, HER2/neu-negative breast cancer [abstract]. In: 2014 ASCO Annual Meeting, Chicago, Illinois, May 30-June 3, 2014. J Clin Oncol 32, 2014, abstr e11515. **Poster presentation**.
67. Song X, **Dent S**, Verma S, Clemons M, Graham N, Bedard M, Paquet L. Predictors of Patient-Reported Toxicities from Endocrine Therapy: Importance of Illness Perceptions, Treatment Beliefs and Fear of Recurrence [abstract]. In: 2014 ASCO Annual Meeting, Chicago, Illinois, May 30-June 3, 2014. J Clin Oncol 31, 2013, Abstract nbr 542. **Poster presentation**.
68. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Mazzarello S, Crawley F, Gertler S, **Dent S**, Song X, Segal R, Dranitsaris G, Clemons M. Patient perceptions about potential side effects and benefits from chemotherapy agents [abstract]. In: 2014 ASCO Annual Meeting, Chicago, Illinois, May 30-June 3, 2014. J Clin Oncol 31, 2013 (abstr 6595). **Poster presentation**.
69. Enright KA, Grunfeld E, Lingsong Y, Moineddin R, Ghannam M, **Dent S**, Eisen A, Trudeau M, Kaizer L, Earle C, Krzyzanowska MK. Monitoring acute care utilization during adjuvant chemotherapy for early breast cancer as a measure of quality [abstract]. In: ASCO Quality Care Symposium, San Diego, California - November 30-December 1, 2012. **Poster discussion**.
70. **Dent S**, Campbell M, Crawley F, Clemons M. The impact of musculoskeletal toxicity on adherence to endocrine therapy in women with early stage breast cancer – observations in a non-trial setting [abstract]. In: 2012 CTRC-AARC San Antonio Breast Cancer Symposium, San Antonio, Texas - December 4-8, 2012. **Poster presentation**.
71. Enright KA, Grunfeld E, Lingsong Y, Moineddin R, **Dent S**, Eisen A, Trudeau M, Kaizer L, Earle C, Krzyzanowska MK. Acute care utilization (ACU) among women receiving adjuvant chemotherapy for early breast cancer (EBC) [abstract]. In: 2012 CTRC-AARC San Antonio Breast Cancer Symposium, San Antonio, Texas - December 4-8, 2012. Abstract nbr 65. **Poster discussion**.
72. Kwong A, Visram H, Graham N, Balchin K, Petrich W, **Dent S**. Treatment Outcomes for Early Stage Male Breast Cancer: A Single Centre Retrospective Case-Control Study [abstract]. In: 2012 CTRC-AARC San Antonio Breast Cancer Symposium, San Antonio, Texas - December 4-8, 2012. **Poster presentation**.

73. Zhu X, Graham N, Paquet L, **Dent S**, Song X. Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, HER2/neu Negative Breast Cancer [abstract]. In: 2012 CTRC-AARC San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, Texas. Abstract nbr 851448. **Poster presentation.**
74. O'Brien J, Grunfield E, Sussman J, Porter G, Paszat L, **Dent S**, Hammond M. Practical Issues in Designing a Qualitative Study as a Follow-up to a Randomized Controlled Trial of Survivorship Care Plans for Patient Transition to Primary Care [abstract]. In: North American Primary Care Research Group 40th Annual Meeting, New Orleans, Louisiana - December 1-5, 2012. **Poster presentation.**
75. **Dent S**, Johnson C, Law A, Graham N, Crawley F, Campbell M, Turek M. Clinical outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre [abstract]. In: ICOS VI Annual Meeting 2012, Milan, Italy - September 28-29, 2012. **Oral Presentation.**
76. **Dent S**, Crawley F, Graham N, Campbell M. Vascular toxicities of endocrine therapy in early stage breast cancer: Encouraging observations in a non-trial setting [abstract]. In: 2012 Breast Cancer Symposium, San Francisco, California - September 13-15, 2012. Abstract nbr 68. **Poster discussion.**
77. **Dent S**, Campbell M, Crawley F, Clemons M, Song X. Endocrine therapy in early breast cancer: Encouraging observations in a non-trial setting [abstract]. In: 2012 ASCO Annual Meeting, Chicago, Illinois - June 1-5, 2012. J Clin Oncol 30:2012 [suppl; abstr 587]. **Poster presentation.**
78. Rayson D, Lupichuk S, Chia S, Potvin K, **Dent S**, Tsao M, Prady C, Ellard S, Salim M, Allo G, Ludkovski O, Goodwin R, Wainman N, Walsh W, Farmer P, Eisenhauer E. A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484) [abstract]. In: 2012 ASCO Annual Meeting, Chicago, Illinois - June 1-5, 2012. J Clin Oncol 30:2012 [suppl; abstr 1036]. **Poster presentation.**
79. Gelmon K, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, **Dent SF**, Ellard S, Tonkin KS, Nagarwala YM, Pritchard KI, Whelan TJ, Nomikos D, Chapman JAW, Parulekar W. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer; Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919 [abstract]. In: 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 1-5, 2012. Abstract nbr LBA671. **Oral abstract session.**
80. Zhu X, Graham N, Paquet L, **Dent S**, Song X. Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, HER2/neu Negative Breast Cancer [abstract]. In: 8th European Breast Cancer Conference, Vienna, Austria - March 21-24, 2012. Abstract nbr 0594. **Poster presentation.**
81. Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, **Dent S**. Sexual dysfunction in women with early stage breast cancer on endocrine therapy: encouraging results from a prospective study [abstract]. In: 2011 CTRC-ARCC San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 6-10, 2011. **Poster discussion PD04-04.**
82. Samiee S, Berardi P, Bougamin N, Vandermeer L, Arnaout A, Mirsky D, **Dent S**, Caudrelier J, Chasen M, Clemons M. Excision of the primary tumour in patients with metastatic breast cancer – will E2108 provide the definitive answer? [abstract]. In: 2011 CTRC-ARCC San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 6-10, 2011. **Poster presentation P2-15-05.**
83. Song X, Verma S, **Dent S**, Clemons M, Graham N, Bedard M, Paquet L. A 1-year prospective longitudinal study of the role of psychological factors in adherence to adjuvant endocrine therapy in early breast cancer [abstract]. In: 2011 CTRC-ARCC San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 6-10, 2011. **Poster presentation OT3-02-01.**
84. Bouganim N, Dranitsaris G, Vandermeer L, Hopkins S, **Dent S**, Wheatley-Price P, Young C, Clemons MJ. Prospective validation of risk prediction models for acute and delayed chemotherapy induced nausea and vomiting (CINV) [abstract]. In: 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J. Clin Oncol 29:2011 [suppl; abstr 6103]. **Poster presentation.**
85. Bouganim N, Hilton JF, Vandermeer L, Hopkins S, Robbins D, Amir E, **Dent S**, Milano C, Freedman OC, Dent RA, Dranitsaris G, Clemons MJ. A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH Trial [abstract]. In: 2011 American Society of

Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J Clin Oncol 29:2011[suppl; abstr 6103]. **Poster presentation.**

86. Chan KK, Trudeau ME, Eisen A, Verreault JL, Freedman CA, **Dent S**. The cost-effectiveness of primary prophylaxis with granulocyte colony-stimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: The impact of risk of febrile neutropenia and its mortality [abstract]. In: 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J Clin Oncol 29:2011 [suppl; abstr 6086]. **Poster presentation.**
87. Grunfeld E, Levine MN, Julian JA, Pond GR, Maunsell E, Folkes A, **Dent SF**, Joy AA, Paszat LF, Pritchard KI, Porter GA, Rayson D, Robidoux A, Smith S, Sussman J, Provencher L, Wiernikowski, Sisler JJ and FUIII Trial Investigators; Ontario Clinical Oncology Group. Results of a multicentre randomized trial to evaluate a survivorship care plan for breast cancer survivors [abstract]. In: 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J Clin Oncol 29:2011 [suppl; abstr 9005]. **Poster presentation.**
88. Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Mirsky D, **Dent S**, Caudrelier JM, Chasen MR, Clemons M: Does removal of a primary tumour in patients with metastatic breast cancer improve either local control or overall survival? In: 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J Clin Oncol 29:2011 [suppl; abstr e11511]. **Poster presentation.**
89. Parulekar W, Chapman JW, Aparicio S, Murray Y, Boyle FM, di Leo A, Kaufmann B, Levy C, Manikhas A, Martin M, Pritchard KI, Schwartzberg LS, Burnell MJ, **Dent S**, Ellard S, Tonkin KS, Whelan TJ, Lemieux J, Bordeleau L, Gelmon KA. Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG) MA.31/ GSK EGF 108919) [abstract]. In: 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 3-7, 2011. J Clin Oncol 29:2011 [suppl; abstr TPS108]. **Poster presentation.**
90. Dranitsaris G, Bouganim N, Vandermeer L, Hopkins S, **Dent S**, Wheatley-Price P, Young C, Clemons M. Prospective validation of risk prediction models for acute and delayed chemotherapy induced nausea and vomiting [abstract]. In: MASCC/ISOO 2011 International Symposium, Athens, Greece - June 23-25, 2011. **Poster presentation.**
91. **Dent S**, Frechette D, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Asmis T, Graham N, Paquet L. How common is sexual dysfunction among women with early stage breast cancer? [abstract]. In: 2010 CRTCC-ARCC San Antonio Breast Cancer Symposium, San Antonio, Texas - December 8-12, 2010. **Poster presentation P2-12-02.**
92. Gelmon K, **Dent S**, Chi K, Jonker D, Wainman N, Simpson R, Capier K, Chen E, Squires MS, Seymour L. NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion [abstract]. In: 2010 EORTC-NCI-AACR Symposium, Berlin, Germany - November 16-19, 2010. EJC 8(7):2010 [suppl; abstr 512]. **Poster presentation.**
93. Paquet L, Frechette D, **Dent S**, Song X, Verma S. Sexual distress in early breast cancer (EBC) survivors [abstract]. In: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois - June 4-8, 2010. J Clin Oncol 28, 2010 [suppl; abstr e19595]. **Poster presentation.**
94. Sousa BA, Buckman RA, Clemons M, **Dent SF**, Wong NS, Kerbel R, Sutherland DJ, Emmenegger U, Gardner S, Pritchard KI. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC) [abstract]. In: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, Illinois. J Clin Oncol 28:15S, 2010 [suppl; abstr 1152]. **Poster presentation 41C.**
95. Hopkins S, Verma S, **Dent S**, Caudrelier J, Song X, Seely J, Watters J. Development of a clinical breast cancer database application for the ongoing quality assurance of breast cancer care [abstract]. In: European Breast Cancer Conference, Barcelona, Spain - March 24-27, 2010. Abstract nbr 531. **Poster presentation.**
96. Song X, Graham N, **Dent S**, Hopkins S, Verma S. Adjuvant endocrine therapy in premenopausal women – toxicities and adherence rates from a tertiary care centre [abstract]. In: European Breast Cancer Conference, Barcelona, Spain - March 24-27, 2010. Abstract nbr 38. **Poster presentation.**
97. Visram H, Kanji F, **Dent S**. Overall and disease free survival in males with early stage breast cancer compared to females: a retrospective matched cohort study from a single tertiary care cancer centre [abstract]. In: 27th Annual Miami Breast Cancer Conference, Miami, Florida - March 3-6, 2010. **Poster Presentation.**

98. Alkhayyat SS, **Dent SF**, Verreault JL, Robinson AG, Germond C, Vanderberg TA. Incidence of Febrile Neutropenia with Taxane-Based Systemic Therapy in Women with Early Stage Breast Cancer [abstract]. In: 2010 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 9-13, 2009. *Cancer Res* 69:24. **Poster presentation.**
99. **Dent S**, Law A, Johnson C, Verreault J, Graham N, Finnigan J, Turek M. Diagnosis and treatment of cardiotoxicity: Establishment of a cardiac oncology clinic at a tertiary care center [abstract]. In: 2009 Breast Cancer Symposium, San Francisco, California - Oct 8-10, 2009. Abstract nbr 168. **Poster presentation.**
100. Amir E, Freedman O, Dranitsaris G, Napolskikh J, Chia S, Petrella T, **Dent S**, Kumar R, Fralick M, Clemons M. Developing a Prediction Model For Benefit From Fulvestrant In Heavily Pretreated Metastatic Breast Cancer Patients [abstract]. In: 2009 ASCO Annual Meeting, Orlando, Florida - May 29-June 2, 2009. *J Clin Oncol* 27:15s, 2009 [suppl; abstr 1041]. **Poster presentation.**
101. Taylor S, Chia S, **Dent S**, Clemons M, Greci P, Wang L, Oza A, Ivy P, Pritchard K, Leigh N. A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I. A trial of the Princess Margaret Hospital Phase II Consortium [abstract]. In: 2009 ASCO Annual Meeting, Orlando, Florida - May 29-June 2, 2009. *J Clin Oncol* 27:15s, 2009 [suppl; abstr 1133]. **Poster presentation.**
102. Visram H, **Dent S**. Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center [abstract]. In: 2009 ASCO Annual Meeting, Orlando, Florida - May 29- June 2, 2009. *J of Clin Oncol* 27:2009 [supple; abstr e11613]. **Poster presentation.**
103. Verma S, **Dent S**, Paquet L, Bitonti L. When the BRCA test is negative - Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA) [abstract]. In: 2008 ASCO Annual Meeting, Chicago, Illinois - May 30-June 3, 2008. *J Clin Oncol* 26:2008 [May 20 Suppl; abstr 1534]. **Poster presentation.**
104. Verma S, **Dent S**, Manthorne J, Song X, Hopkins S, Ferlaino C. Informational and supportive needs of women considering extended hormonal adjuvant treatment: A Canadian survey conducted by SOLARIS [abstract]. In: European Breast Cancer Conference, Berlin, Germany - April 15-19, 2008. **Poster presentation.**
105. **Dent S**, Hopkins S, Di Valentin T, Verreault J, Vandermeer L, Verma S. Adjuvant aromatase inhibitors in early breast cancer - toxicity and adherence: Important observations in clinical practice [abstract]. In: 2007 CTRC-AARC San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 13-16, 2007. **Poster presentation.**
106. Song X, Nicholas G, **Dent S**, Verma S. Adjuvant hormonal therapy in women with early stage breast cancer [abstract]. In: 2007 CTRC-AARC San Antonio Breast Cancer Symposium, San Antonio, Texas - Dec 13-16, 2007. **Poster presentation 2106.**
107. **Dent S**, Vandermeer L, Verreault J, Hopkins S, Azzi J, Verma S. Adherence to adjuvant trastuzumab in early stage breast cancer [abstract]. In: 2007 Breast Cancer Symposium, San Francisco, California - September 7-8, 2007. Abstract nbr 239. **Poster presentation.**
108. Chia S, **Dent S**, Ellard S, Ellis P, Vandenberg T, Gelmon K, Powers J, Seymour L, Eisenhauer E. A phase II trial of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel in metastatic breast cancer: NCIC CTG IND 164 trial [abstract]. In: 2007 ASCO Annual Meeting, Chicago, Illinois - June 1-5, 2007. *Proc Am Assoc Cancer Res* 48, 836. **Poster presentation.**
109. **Dent S**, Vandermeer L, Spaans J, Verreault J, Azzi J, Hopkins S, Verma S. Adjuvant trastuzumab in early stage breast cancer: Is cardiac dysfunction clinically significant [abstract]. In: 2007 ASCO Annual Meeting, Chicago, Illinois - June 1-5, 2007. *J Clin Oncol* 25:18S, 2007 [suppl; abstr 11072]. **Poster presentation.**
110. Song X, Nicholas G, **Dent S**, Verma S. Adjuvant hormonal therapy in women with early stage breast cancer [abstract]. In: 2007 ASCO Annual Meeting, Chicago, Illinois - June 1-5, 2007. *J Clin Oncol* 25:18S, 2007 [suppl; abstr 11053]. **Poster presentation.**
111. **Dent S**, DiValentin T, Vandermeer L, Spaans J, and Verma S. Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center [abstract]. In: 2006 CTRC-AARC San

Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. *Breast Cancer Res Treat.* 100:S190, 2006 [suppl 1; abstr 4057]. Poster presentation.

112. **Dent S**, Verma S, Azzi J, Vandermeer L, Spaans J. Outcomes in locally advanced breast cancer with systemic therapies: data from a regional tertiary care cancer centre [abstract]. In: 2006 CTRC-AARC San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. Poster presentation.
113. Paquet L, Verma S, Collins B, Song X, Wheatley-Price P, Hopkins S, Segal R, **Dent S**, Mirsky D, Goel R, Young V, Clemons M, Keller O, Chinneck A, Young R, Bedard M. High prevalence of prospective memory (PM) impairment in early breast cancer (EBC) survivors within 1 year of adjuvant chemotherapy completion: novel findings concerning post chemotherapy cognitive effects [abstract]. In: 2006 CTRC-AARC San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. Poster presentation P4-15-01.
114. **Dent S**, Gertler S, Verma S, Segal R, Young V, Haq A, Goel R, Keller O, Canil C, Iscoe N. A Phase II Study of Biweekly Pemetrexed (PEM) and Gemcitabine (GEM) in Patients with Metastatic Breast Cancer [abstract]. In: ESMO Annual Meeting; Sep 29- Oct 3, 2006; Istanbul, Turkey.
115. **Dent S**, Verma S, Azzi J, Vandermeer L, Spaans J. Trends in systemic management (SM) for the treatment of locally advanced breast cancer: Data from a regional cancer centre [abstract]. In: 2006 ASCO Annual Meeting; June 2-6, 2006; Atlanta, Georgia. Abstract nbr 10728.
116. Grunfeld E, Julian J, Levine M, Pritchard K, Coyle D, **Dent S**, Verma S, Mirsky D, Sawka C, Ginsburg D, Wood M. A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes [abstract]. In: 2006 ASCO annual meeting; June 2-6, 2006; Atlanta, Georgia. *J Clin Oncol* 24:18S, 2006 [suppl; abstr 6003]. Oral abstract session.
117. Lethbridge L, Grunfeld E, Dewar R, Johnston G, McIntyre P, Lawson B, Burge F, **Dent S**, Paszat L, Earle C. Quality indicators for end-of-life breast cancer care: Testing the use of administrative databases [abstract]. In: 2006 ASCO annual meeting; June 2-6, 2006; Atlanta, Georgia. Abstract nbr 6066. Poster Presentation.
118. McIntyre P, Grunfeld E, Mykhalovskiy E, Cicchelli L, **Dent S**, Zitzelsberger L, Paszat L, Earle C. Quality indicators for end-of-life breast cancer care: Is there agreement between stakeholder groups? [abstract]. In: 2006 ASCO annual meeting; June 2-6, 2006; Atlanta, Georgia. Abstract nbr 16034.
119. Segal R, **Dent S**, Verma S, Canil C, Azzi J, Vandermeer L, Spaans J. Changing demographics of locally advanced breast cancer: Data from a regional cancer centre [abstract]. In: 2006 ASCO Annual Meeting; June 2-6, 2006; Atlanta, Georgia. Abstract nbr 10780.
120. Hopkins S, Gertler S, Verma S, **Dent S**, Nicholas G, Bastianelli P. Dose intensity of epirubicin-based adjuvant breast cancer therapy: FEC100 vs CEF/PO [abstract]. In: European Breast Cancer Conference; Mar 21-25, 2006; Nice, France. Abstract nbr 361.
121. Hopkins S, Nicholas G, Verma S, **Dent S**, Gertler S. Relative dose intensity of FEC100: An analysis of outcomes [abstract]. In: 2005 ASCO Annual Meeting; May 14-17, 2005; Orlando, Florida. Abstract nbr 773.
122. Hopkins S, Verma S, **Dent S**, Gertler S, Segal-Nadler R, Bastianelli P. Adjuvant FEC100: Relative Dose Intensity in an Academic Outpatient Practice [abstract]. In: 2004 CTRC-AARC San Antonio Breast Cancer Symposium; Dec 8-11, 2004; San Antonio, Texas. Abstract nbr 6036. Poster presentation.
123. Leighl N, Warr D, Vandenberg T, **Dent S**, Tannock I, Crump M, Tozer R, Dancey J, Moore M. Phase II study of perifosine in metastatic or advanced breast cancer [abstract]. In: 2004 CTRC-AARC San Antonio Breast Cancer Symposium; Dec 8-11, 2004; San Antonio, Texas. Abstract nbr 1077. Poster presentation.
124. Saginur R, **Dent SF**, Laviolette MA, Hesgrave R, Schwartz L, Hodinott S, Zanke B, Stacey S. The Ontario Cancer Research Ethics Board (OCREB): A model Regional IRB [abstract]. In: 19th Annual Meeting of the Applied Research Ethics National Association (ARENA); Oct 28-31, 2004; San Diego, California. Abstract nbr 32. Poster presentation.
125. **Dent S**, Saginur R, Stacey S, Hesgrave R, Zanke B. Ontario Cancer Research Ethics Board (OCREB): A central research ethics board initiative [abstract]. In: 2004 ASCO Annual Meeting; Jun 5-8, 2004; New Orleans, Louisiana. *J Clin Oncol* 22:14S, 2004 (suppl; abstr 6094).

126. Grunfeld E, Levine M, Julian J, Pritchard K, Coyle D, **Dent S**, Ginsburg D, Sawka C, Verma S, Wood M. Ontario Clinical Oncology Group and Ottawa, Hamilton, Thunder Bay and Kingston Regional Cancer Centres. A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: a comparison of primary care versus specialist care [abstract]. In: 2004 ASCO Annual Meeting; Jun 5-8, 2004; New Orleans, Louisiana. *J Clin Oncol* 23:14S, 2004 [suppl; abstr 665]. Poster presentation.
127. Jonker D, Ayruich L, Stewart D, Goel R, Goss G, **Dent S**, Reaume M, Spencer T, Peters W. A phase 1 safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumours stratified according to N-cadherin expression [abstract]. In: 2004 ASCO Annual Meeting; Jun 5-8, 2004; New Orleans, Louisiana. *J Clin Oncol* 22:14S, 2004 [suppl; abstr 3078]. Poster presentation
128. **Dent S**, Gehman T. Family Physicians' Awareness of Risk Assessment for Young Women at Risk of Developing Breast Cancer [abstract]. In: 2003 CRTC-AARC San Antonio Breast Cancer Symposium; Dec 3-6, 2003; San Antonio, Texas. Abstract nbr 616. Poster presentation.
129. Fitzgibbon E, Meng J, Samant R, **Dent S**, Graham I. If family physicians knew how effective palliative radiotherapy could be, would they refer? [abstract]. In: 2003 ASCO Annual Meeting; May 31-Jun 3, 2003; Chicago, Illinois. *Proc Am Soc Clin Oncol* 22:2003 (abstr 3072). Poster Presentation.
130. Maroun J, Jonker D, Goel R, Cripps C, **Dent S**, Kocha W, Seymour L, Fisher B. A phase I/II study of triple drug combination of CPT-11, oxaliplatin and Tomudex in previously untreated patients with metastatic colorectal cancer: Final results. NCIC Clinical Trials Group, IND.135 [abstract]. In: 27th ESMO Congress; October 18-22, 2002; Nice, France. *Ann.Oncol.* 13(Suppl. 5), 76, 2002.
131. **Dent S**, Sellick S, Cranston K, Setliff A, Way M, Steggles S, Cechetto S, Spadafora S, Bettello P. Patients' perception of participation in a Phase III Clinical Trial at a Regional Cancer Center (RCC) [abstract]. In: 2002 ASCO Annual Meeting; May 18-21, 2002; Orlando, Florida. *Proc Am Soc Clin Oncol* 21:2002 (abstr 2589).
132. Maroun J, Jonker D, Goel R, Cripps C, **Dent S**, Fisher B, Seymour L, Kocha W. Phase I study of triple drug combination of CPT-11, oxaliplatin and tomudex in previously untreated patients with metastatic colorectal cancer: NCIC Clinical Trials Group IND.135 [abstract]. In: 2002 ASCO annual meeting; May 18-21, 2002; Orlando, Florida. *Proc Am Soc Clin Oncol* 21:2002 (abstr 571). Poster presentation.
133. **Dent S**, Arnold A, Stewart D, Gertler S, Ayoub J, Batist G, Goss G, Neville A, Soulieres D, Jolivet J, McIntosh L, Seymour L. NCIC CTG IND 120: phase II study of Troxacitabine (BCH-4556) in patients with advanced non-small cell lung cancer [abstract]. In: 2001 ASCO Annual Meeting; May 12-15, 2001; Philadelphia, Philadelphia. *Proc Am Soc Clin Oncol* 20, 259b, 2001.
134. Reyno L, Seymour L, Tu D, Pearce L, **Dent S**, Gelmon K, Walley B, Pritchard K, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Lebwohl D. Phase III study of DPPE (BMS217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: a NCIC Clinical Trials Group study [abstract]. In: 2001 ASCO Annual Meeting; May 12-15, 2001; Philadelphia, Philadelphia. *Proc Am Soc Clin Oncol* 20, 30a, 2001.
135. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, **Dent S**, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, O'Connor A, Bodendorfer I. A randomized trial of a decision aid for the use of adjuvant chemotherapy in women with node-negative breast cancer [abstract]. In: 2001 ASCO Annual Meeting; May 12-15, 2001; Philadelphia, Philadelphia. *Proc Am Soc Clin Oncol* 20, 946, 2001.
136. Khoo K, Brandes L, Reyno L, **Dent S**, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer: a NCIC Clinical Trials Group study [abstract]. In: 1998 ASCO annual meeting; May 17-19, 1998; Los Angeles, California. *Ann.Oncol* 9(2), 171, 1998; *Proc ASCO* 17:152.
137. **Dent S**, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer [abstract]. In: 1997 ASCO Annual Meeting; May 17-20, 1997; Denver, Colorado. *Proc Am Soc Clin Oncol* 16: 353, 1997.
138. Trudeau M, Eisenhauer E, **Dent S**, Pritchard K, Lofters W, Norris B, Muldal A, Letendre F, Vandenberg T, Verma S. Central nervous system relapse following chemotherapy with docetaxel for metastatic breast cancer. Update of a

study by the NCIC Clinical Trials Group [abstract]. In: 1996 ASCO Annual Meeting; May 18-21, 1996; Philadelphia, Philadelphia. Proc Am Soc Clin Oncol 15:101, 1996.

139. Eisenhauer EA, **Dent S**. Phase I Trial Design - Can it be improved? [abstract]. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Queen's University, Kingston, Canada. In: 6th International Congress on Anticancer Treatment; Feb 6-9, 1996; Paris, France.
140. **Dent S**, Bociek G. Prophylactic Anticonvulsants for cancer patients with newly diagnosed brain metastases. National Cancer of Canada Clinical Trials Group, Queen's University, Kingston, Ontario [abstract]. In: 1996 ASCO Annual Meeting; May 18-21, 1996; Philadelphia, Philadelphia. Abstract nbr 1710.
141. **Dent S**, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart DJ. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphoma [abstract]. In: 1994 ASCO Annual Meeting; May 14-17, 1994; Dallas, Texas. Abstract nbr 1653.

INVITED LECTURES

International

1. Practice Guidelines/Position Statements: Pearls To Take Home. 2018 MSK Cardio-Oncology Symposium. MSKCC, New York, NY May 19th, 2018
2. Cardio-Oncology Network for Patients. 2nd Cardiooncology Colloquium, Krakow, Poland May 4th, 2018
3. Surveillance Strategies in adult cancer patients treated with anthracyclines and HER2 targeted therapy, 1st Symposium in Cardio-Oncology Argentina, Buenos Aires, Argentina, April 19th, 2018
4. Implications of QT interval in Cancer Therapy – an oncologists perspective, 1st Symposium in Cardio-Oncology Argentina, Buenos Aires, Argentina, April 20th, 2018
5. Cancer and the Heart: Overview of Cardiotoxicity: An oncologist's perspective. Florida Hospital Cardiovascular Grand Rounds, Orlando, Florida March 28th, 2018
6. Establishment of a cardio-oncology clinic – where to start?, Cardio-oncology and Cardiometabolic Prevention meeting. Dominican Society of Cardiology. Santo Domingo Dominican Republic. February 16th, 2018
7. Cardiotoxicity in adult cancer survivors – Is it a problem? Cardio-oncology and Cardiometabolic Prevention meeting. Dominican Society of Cardiology. Santo Domingo Dominican Republic. February 16th, 2018
8. Cancer and the heart – overview of cardiotoxicity: Oncologists perspective. III Simposio Internacional de Cardio-Oncologia Sao Paulo, Brazil, November 17, 2017
9. HER-2 targeted therapies and new anti-breast cancer agents. III Simposio Internacional de Cardio-Oncologia Sao Paulo, Brazil, November 17, 2017
10. Research in cardio-oncology: Gaps and opportunities. III Simposio Internacional de Cardio-Oncologia Sao Paulo, Brazil, November 17, 2017
11. Best Practices for CV monitoring. Implications of real-time safety data in oncology clinical trials. Cardiac Safety Research Consortium. FDA Silver Springs MD. October 24th, 2017
12. Inhibitors CDK4/6: The beginning of a new era in the treatment of advanced breast cancer. SMEO, Mexican Society of Oncology, Queretaro City, Mexico October 20th, 2017
13. Cyclin Dependent Kinase Inhibition: A revolution in endocrine therapy. 12th Edition Breast Cancer, Gramado, Brazil, September 1st, 2017

14. How much should we worry about late cardiotoxicity after adjuvant therapy? 12th Edition Breast Cancer, Gramado, Brazil, August 31st, 2017
15. Decisions Guiding Treatment Sequence for Endocrine Sensitive HER-2 negative Advanced Breast Cancer. Rounds, Sao Paulo, August 29th, 2017 and Rio Di Janeiro August 30th, 2017.
16. Can collaboration between oncologist and cardiologists improve care for cancer patients, National Cardio-oncology Summit 2017, Kochi, India, July 30th, 2017
17. Establishing a cardio-oncology clinic, National Cardio-oncology summit 2017, Kochi, India, July 30th, 2017
18. Establishing a Cardio-oncology clinic: 2017 Memorial Sloan Kettering Cardio-Oncology Symposium, New York, New York, May 13th, 2017
19. Cardiovascular Oncology from the perspective of an oncologist: 17th Annual Benjamin Schuster Colloquium. Dayton, Ohio. February 21, 2017
20. Breast cancer treatment and cardiovascular risk. American College of Cardiology Education Course in Cardio-Oncology. Washington, DC. February 17th, 2017.
21. International share: lessons, risks and opportunities in cardio-oncology. First China Cardio-Oncology Conference, Dalian Medical University, Dalian, China, November 18th, 2016
22. Managing Breast Cancer Patients with Heart Disease: An Oncologists' Perspective. Fourth International Conference on Cancer and the Heart, MD Anderson Cancer Center, Houston, Texas, November 4th, 2016
23. Cardio-oncologist View on Breast Cancer. 3rd Meeting on Women Cardiovascular Health Cardio Femme 2016. Haifa Israel, June 24th, 2016.
24. Can cooperation and collaboration between oncologists and cardiologists improve care for cancer patients? Inaugural Duke Cardio-Oncology Symposium. Duke University, Durham, North Carolina, March 5, 2016
25. *Establishing a cardio-oncology clinic. Global Cardio-Oncology Summit. Nashville, Tennessee, October 16th, 2015*
26. *Prevention and treatment of cardiotoxicity. Cardiotoxicity related to breast cancer treatment. Santiago, Chile – May 6, 2015.*
27. *Management of cardiotoxicity in breast cancer patients. Cardiotoxicity related to breast cancer treatment. Santiago, Chile – May 5, 2015.*
28. *What we know and what we should know about cardiovascular effects of systemic therapy in breast cancer. Cardiotoxicity related to breast cancer treatment. Concepcion, Chile – May 4, 2015.*
29. *Cardio-oncology: A Medical Oncologist's Perspective. American College of Cardiology (ACC) 64th Annual meeting, Cardio-oncology Intensive, San Diego, California - March 16, 2015.*
30. *Issues of chemotherapy induced cardiotoxicity in patients with breast cancer. XIII Annual conference on Evidence based Management of Cancers in India, Tata Memorial Hospital, Mumbai, India - Feb 27, 2015.*
31. *Cardiotoxicity and Tyrosine Kinase inhibitors. XIII Annual Conference on Evidence Based Management of Cancers in India, Tata Memorial Hospital, Mumbai, India - Feb 27, 2015.*
32. *Primary prevention of cardiotoxicity. XIII Annual conference on Evidence based Management of Cancers in India, Tata Memorial Hospital, Mumbai, India - Feb 28, 2015.*
33. *Advances in the management of HER2 positive early stage breast cancer. Medical Oncology Meeting, Abu Dhabi, United Emirates - November 7, 2014.*
34. *Chemotherapy and cardiotoxicity: Important issues impacting Women's Health. American Association for Clinical*

Chemistry (AACC) Annual meeting, Chicago, Illinois - July 29, 2014.

35. *How do oncologists and cardiologist integrate care?* International CardiOncology Society (ICOS) meeting, Washington, DC - December 13, 2013.
36. *Cardiac Oncology: What have we learned and where are we going?* Cancer and the Heart, University of Texas MD Anderson Cancer Centre, Houston, Texas - November 4, 2013.
37. *Dexrazoxane: Does it protect the heart?* Cardiotoxicity Collaborative Group Meeting Oxford, England - October 2, 2013.
38. *Evolving Standard of Care in HER2 positive Early Stage Breast Cancer.* Oncology Conference, Dhaka, Bangladesh - August 30, 2013.
39. *Clinical outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* International CardiOncology Society (ICOS) Meeting, Milan, Italy - September 21, 2012.
40. *Triple Negative Breast Cancer: Challenges and Opportunities.* Oncology Rounds/Resident Talk. Dublin, Ireland - April 8, 2011.
41. *Taxanes in the treatment of metastatic breast cancer – have we made progress?* 5th Shanghai Breast Cancer Forum, Shanghai, China - November 6th, 2010.
42. *Challenges in the systemic management of locally advanced breast cancer,* Taipei International Breast Cancer Symposium, Taipei, Taiwan - September 5, 2010.
43. *Novel Targeted Therapies in HER-2 negative Metastatic Breast Cancer.* Chemotherapy Foundation Symposium XXVII, New York City, New York, U.S. - November 2009.
44. *Improving Medical Outcomes in Metastatic Breast Cancer.* National Cancer Research Institute Cancer (NCRI) Conference, Birmingham, England - October 6, 2009.
45. *Update of Second Primary Malignancies and Treatment Results in Women with Early Stage Ovarian Cancer”* Presented at Gynecological Oncology Session, ASCO, Denver, Colorado, 1997

National

46. Update on Breast Cancer. Canadian Summer Oncology Update, Whistler B.C. June 23rd, 2018
47. Oncology and Academic Medicine – A Canadian Perspective. 16th Annual Oncology Research Day, Department of Radiation and Medical Oncology. Dalhousie University, Halifax, May 24th, 2018
48. Hormone Receptor Positive Breast Cancer – How to treat in 2017. Canadian Association of General Practitioners in Oncology Annual Meeting, Montreal, Quebec, September 30, 2017
49. Hormone Receptor Positive Advanced Breast Cancer: should CDK 4/6 inhibitors be considered standard of care? Canadian Breast Cancer Symposium, Toronto, Ontario, June 22, 2017.
50. Cancer and the heart: What have we learned and where are we going? Canadian Association of General Practitioners in Oncology. Annual Meeting. Gatineau, Quebec. October 4th, 2015.
51. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – April 20, 2015.
52. *Is your patient at risk for chemotherapy-induced neutropenia? A look at formalizing risk assessment.* Canadian Association of Nurses in Oncology (CANO) Annual Meeting, Quebec City, QC - October 28, 2014.
53. *Mitigating the Risk of Treatment-Associated Cardiotoxicity in Breast Cancer.* Oncology Rounds, Vancouver BC -

54. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – October 6, 2014.
55. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – May 12, 2014.
56. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – April 28, 2014.
57. *Clinical Considerations in Chemotherapy Induced Toxicity: What have we learned?* St. John’s New Brunswick, October 16, 2013.
58. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – September 16, 2013.
59. *Clinical Trials Infrastructure.* 4th biennial New Investigators Clinical Trials Course , National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG), Kingston, Ontario - August 21, 2013.
60. *Metastatic breast cancer in 2013-what have we learned and where are we going?* Atlantic Clinical Oncology Group (ACOG) Annual Meeting, Halifax, Nova Scotia - June 14, 2013.
61. *Cardiotoxicity – Getting to the heart of the matter!* Oncology Rounds, Montreal, Quebec - May 1, 2013.
62. *Clinical Outcomes of patients referred to a cardiac oncology clinic in a tertiary care centre.* Cardiac Oncology Preceptorship Program, Ottawa, Ontario – April 22, 2013.
63. *Early Breast Cancer.* 18th Annual National Canadian Preparatory Course, Ottawa, Ontario – February 2013.
64. *Taxanes in the treatment of metastatic breast cancer – have we made progress?* Oncology Grand Rounds, Montreal, QC – February 2012.
65. *Treatment of metastatic breast cancer: Challenges and Opportunities.* Medicine Grand Rounds, St. Mary’s Hospital, Montreal, Quebec – September 2011.
66. *Early Breast Cancer.* 16th Annual National Canadian Preparatory Course, Ottawa, Ontario – January 2011.
67. *Prevention and Treatment of febrile neutropenia in early stage breast cancer: a changing landscape.* National Oncology Pharmacy Symposium (NOPS), Winnipeg, MB - October 15, 2010.
68. *The Treatment of triple negative breast cancer: where do we go from here?* Atlantic Canada Clinical Oncology Group (ACOG) Annual Meeting. Charlottetown, PEI – June 17-19, 2010.
69. *Cardiotoxicity and Novel Cancer Compounds – Should we be concerned?* Atlantic Canada Clinical Oncology Group (ACOG) Annual Meeting, Charlottetown, PEI – June 17-19, 2010.
70. *Multidisciplinary Approach to Locally Advanced/Inflammatory Breast Cancer.* Canadian Consortium for Locally Advanced Breast Cancer (LABC) Conference, Cambridge, Ontario – April 11-12, 2010.
71. *Metastatic Breast Cancer: Treatment Options in 2009.* Congres des Chirurgiens du Quebec Annual Meeting, Quebec City, QC - May 21, 2009.
72. *Adjuvant Hormonal Therapy in Breast Cancer: The Aches and Pains.* Oncology Rounds. Montreal, Quebec - January 14, 2009.
73. *Early Breast Cancer.* 14th Annual National Canadian Preparatory Course, Ottawa, Ontario – January 2009.
74. *Optimizing Cardiac Care in HER2-positive Early Breast Cancer.* Oncology Rounds, Jewish General Hospital, Montreal, QC – Nov 2008.

75. *Optimizing Cardiac Care in HER2-positive Early Breast Cancer*. Oncology Rounds, St. Mary's Hospital, Montreal, QC – Nov 2008.
76. *Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group*. Oncology Rounds, St. John, Newfoundland – October 2008.
77. *Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group*. Oncology Rounds, Moncton, New Brunswick – October 2008.
78. *Optimizing Cardiac Care in HER2-positive Early Breast Cancer: Recommendations of the Canadian Trastuzumab Working Group*. National Oncology Pharmacy Symposium (NOPS), Calgary, AB – October 17-19, 2008.
79. *Cardiac Management During Adjuvant Trastuzumab Therapy. Recommendations of the Canadian Trastuzumab Working Group*. Canadian Association of Nurses in Oncology (CANO) Annual Meeting, St. John's, Newfoundland - September 15, 2008.
80. *Metastatic Breast Cancer: The Changing Landscape*. Oncology Rounds, Montreal, QC – May 2008.
81. *Triple Negative Breast Cancer Platinum Based Therapy – is it necessary?* Great Canadian Debate, Sunnybrook Health Sciences Centre, Toronto, Ontario - January 22, 2008.
82. *Metastatic Breast Cancer – The Changing Landscape*. British Columbia Cancer Agency (BCCA) Annual Cancer Conference, Vancouver, British Columbia - November 30, 2007.
83. *Metastatic Breast Cancer. The Changing Landscape*. Canadian Association of General Practitioner's in Oncology (CAGPO) Annual Meeting, Ottawa, Ontario - November 1, 2007.
84. *Thought to Therapy: The Evolving Approach to Early Hemoglobin Management in Breast Cancer*. CME-Accredited Talk at Faculty Development Program, Montreal, Quebec - Apr 2006
85. *The 21st Century: The Dawn of a new Era in Cancer Therapeutics* Presented at the National Oncology Pharmacy Symposium 9, Toronto, Ontario – Apr 1996
86. *Adjuvant Chemotherapy in Breast Cancer Workshop* CME Accredited Talk at The Breast Cancer Course, Quebec City, Quebec – Mar 2005
87. *Optimizing Adjuvant Therapy: Managing the HER2+ Patient with Early Breast Cancer* Presented at the 3rd Annual Meeting – *New Developments & New Choices in Breast Cancer*, Toronto, Ontario – Nov 2005
88. *Finding Nemo in a Sea of Hormones – Treatment Options for Early Stage Breast Cancer* t Grand Rounds, Kingston Regional Cancer Centre, Kingston, Ontario – Feb 2005
89. *Benefits/Risk in Endocrine Adjuvant Therapy for Breast Cancer (BEAT)* Kingston, Ontario – Feb 2005
90. *Advances in Breast Cancer Management* Grand Rounds, Sudbury Regional Cancer Centre, Sudbury, Ontario – May 2005
91. *Best Practices for the Management of Breast Cancer in Ontario 2004 Workshop*” CME-Accredited Talk, Breast Cancer Conference, Merrickville, Ontario – May 2004
92. *Treatment Options in Metastatic Breast Cancer*, Grand Rounds, St. John's, Newfoundland – Jan 2004
93. *Accrual to Clinical Trials* Breast Cancer Retreat, Le Chateau Montebello, Quebec – Nov 2002

Provincial

94. Treatment of HR+HER2- Metastatic Breast Cancer: Treatment options in 2018. Oncology grand rounds, Juravinski Cancer Centre, January 18th, 2018

95. Can Collaboration between Oncologists and Cardiologist improve care for cancer patients? Northwestern Ontario Regional Cancer Center , Grand Rounds, Thunder Bay, Ontario, November 11th, 2016
96. Can Collaboration between oncologist and cardiologist improve care for cancer patients? Breast Disease Site rounds, Sunnybrook Odette Cancer Centre, Toronto, Ontario June 9th, 2016
97. Neoadjuvant Treatment of Breast cancer. Best of San Antonio Breast Cancer Symposium. Oncology Education. Toronto, Ontario. January 22nd, 2016
98. *Is your patient at risk for chemotherapy-induced neutropenia? A look at formalizing risk assessment.* Kingston, Ontario. October 1, 2015
99. *Improving Cardiac Safety, Advancing Cancer Care.* 18th Annual Toronto-Ottawa Heart Summit, Toronto, Ontario – June 20, 2015.
100. *Neoadjuvant Treatment of Breast cancer.* Best of San Antonio Breast Cancer Symposium. Oncology Education, Sunnybrook Estates, Toronto, Ontario - January 16, 2015.
101. *Is your patient at risk for chemotherapy-induced neutropenia? A look at formalizing risk assessment.* Sault Ste. Marie, Ontario - November 5, 2014.
102. *Clinical Considerations in Chemotherapy Induced Toxicity: What have we learned?* Oncology Grand Rounds, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario - June 23, 2014.
103. *Enhancing Patient Safety: Implementation of OPIS2005 to oncology inpatient units at The Ottawa Hospital.* Cancer Care Ontario Provincial Systemic Therapy Committee Meeting, Toronto, Ontario – November 2012.
104. *Taxanes in the Treatment of Metastatic Breast cancer – have we made progress?* Oncology Grand Rounds, Sudbury, Ontario - May 11, 2012.
105. *Prevention and Treatment of Febrile Neutropenia in Early-Stage Breast Cancer: a Changing Landscape.* Oncology Rounds, Quebec City, Quebec – February 2011.
106. *Optimizing Intervention: Case Studies in the Adjuvant Treatment of Breast Cancer.* Oncology Rounds, Sault Ste. Marie, Quebec – October 2009.
107. *Emerging Issues in MBC: Retreatment and Treatment beyond Progression.* Leaders Forum for Innovators in Oncology, Toronto, Ontario – June 2008.
108. *Clinical Research – Challenges in 2007.* Oncology Grand Rounds, Sunnybrook Cancer Center, Toronto, Ontario - November 15, 2007.
109. *Metastatic Breast Cancer: The Changing Landscape.* Oncology Rounds, Princess Margaret Hospital, Toronto, Ontario - September 11, 2007.
110. *Chemotherapy Adjuvant Treatment for Breast Cancer in Young Women (ChAT).* Presented at Rounds, Kingston Regional Cancer Centre, Kingston, Ontario - Apr 2006
111. *Treatment for Early Stage Breast Cancer – Getting to the Heart of the Matter.* Grand Rounds, Kingston Regional Cancer Centre, Kingston, Ontario – Apr 2006
112. *Metastatic Breast Cancer: Treatment Options in 2006* Presented at Northwestern Ontario Regional Cancer Centre, Thunder Bay, Ontario - Apr 2006
113. *Aromatase Inhibitors in Early Stage Breast Cancer* Presented to Nurses and Oncologists at Sault Ste. Marie, Ontario – Nov 2005
114. *Treatment Options in Metastatic Breast Cancer* Grand Rounds, Kingston Regional Cancer Centre, Kingston, Ontario – Nov 2005

115. *Benefit/Risk in Endocrine Adjuvant Therapy for Breast Cancer (BEAT)* CME Accredited Program, Moncton, New Brunswick – Jun 2005
116. *Adjuvant Therapy for Breast Cancer* Grand Rounds, Northwestern Ontario Regional Cancer Centre, Sudbury, Ontario – Jun 2003
117. *Treatment Options in Metastatic Breast Cancer* Presented at Grand Rounds, Kingston Regional Cancer Centre, Kingston, Ontario – Oct 2003
118. *Survivorship*. Northeastern Ontario Oncology Group, Muskoka, Ontario – Jun 2003

Local

119. What's new in HER-2 targeted therapy – SABCS update 2017. Breast Cancer Rounds, Ottawa, Ontario, January 23rd, 2018.
120. Endocrine Therapy in Metastatic Breast Cancer. How to treat in 2017! Annual Ottawa Breast Cancer Retreat. Ottawa, Ontario, October 13th, 2017
121. ASCO 2017 Update in Breast Cancer. The Ottawa Hospital, September 13th, 2017
122. Neutropenia in the cancer patient. Nurses Lunch and Learn. The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada, April 13th, 2017
123. Advanced breast cancer: The changing Landscape. Ottawa, Ontario. January 26th, 2017.
124. Extended duration endocrine therapy in early stage breast cancer. Update from SABCS 2016. Breast Cancer Rounds, Ottawa, Ontario, January 16th, 2017.
125. An update from CCON: Optimizing Cardiac Care and Treatment Options for Patients with Metastatic Breast Cancer. Ottawa, Ontario March 11th, 2016.
126. The Ottawa Cardio-Oncology Program and Malignant Hematology. Hematology Grand Rounds. Ottawa, Ontario, January 29th, 2016
127. Breast Disease Site Group Research Update: Annual Breast Cancer Disease Site Group Annual retreat, Ottawa, Ontario. Breast Cancer Research Update. October 28, 2015
128. Elucidating the mechanisms of right heart failure, Ottawa Heart Institute research rounds. Ottawa, Ontario. October 5th, 2015.
129. *Improving Cardiac Safety, Advancing Cancer Care*. 3rd annual Ottawa Heart Research Conference – Advances in Heart Failure Management: The Science and The Art – April 24, 2015.
130. *Systemic Therapy – Toxicities and management strategies*. TOH Nursing In-Service, Ottawa, Ontario - January 30, 2015.
131. *Breast Cancer Disease Site Group Research Update 2014*. Annual Breast Cancer Meeting, Ottawa, Ontario - November 20, 2014.
132. *Taking Oncology to Heart – Lessons Learned on Sabbatical!* Oncology Grand Rounds. The Ottawa Hospital Cancer Center, Ottawa, Ontario - September 11, 2014.
133. *Cardiac Oncology: Improving Cardiac Safety Advancing Cancer Care*. Department of Medicine Grand Rounds, University of Ottawa, Ottawa, Ontario - April 22, 2014.
134. *Cancer and the Heart – what have we learned and where are we going?* Ottawa's 7th Annual Clinical Day, Ottawa Academy of Medicine, Ottawa, Ontario - February 24, 2014.

135. *Clinical Trials Infrastructure*. New Investigators Course, National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG), Kingston, Ontario – August 2013.
136. *Breast Cancer in 2013 – What have we learned and where are we going?* Radiation Oncology Academic Half Day, Ottawa, Ontario – April 2013.
137. *Department of Medicine Milestones 2013*. The Ottawa Hospital Quality Committee Board, Ottawa, Ontario - January 9, 2013.
138. *Clinical Research – Current Challenges & Future Opportunities*. Breast Cancer Disease Site Group Retreat, Ottawa, Ontario - October 11, 2012.
139. *Systemic Therapy of Breast Cancer – an Update*. Breast Cancer Disease Site Group Retreat, Ottawa, Ontario – October 11, 2012.
140. *American Society of Clinical Oncology (ASCO) update*. Oncology Grand Rounds. The Ottawa Hospital Cancer Centre, Ottawa, Ontario - June 13, 2012.
141. *Bringing Oral Agents Up to Standard – Oral Cytotoxic Safety Initiative*. Oral Cytotoxic Safety Initiative, Ottawa, Ontario – June 2012.
142. *Cardiac Toxicity in Oncology*. Oncology Grand Rounds, The Ottawa Hospital Cancer Center, Ottawa, Ontario - February 23, 2012.
143. *Clinical Research - Current Challenges and Future Opportunities*. Breast Cancer Disease Site Group, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - October 12, 2011.
144. *Breast Research Update*. Breast Cancer Disease Site Group, The Ottawa Hospital Cancer Centre, Ottawa, Ontario – September 2011.
145. *Challenges in the Systemic Management of Locally Advanced & Metastatic Breast Cancer*. Oncology Residents' Course, Ottawa, Ontario – September 2011.
146. *Adjuvant Systemic Therapy for early stage breast cancer*. Academic Half Day, University of Ottawa Medical and Radiation Oncology Residents, Ottawa, Ontario – September 2011.
147. *American Society of Clinical Oncology (ASCO) 2011 Update*. Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - June 23, 2011.
148. *Managing febrile neutropenia in regional systemic therapy satellites*. Satellite Chemotherapy Units, Champlain LHIN, Ottawa, Ontario – January 2011.
149. *Clinical trial endpoints in Breast Cancer: in the end, what matters most?* Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario – 2011.
150. *The use of ESA's in Cancer: What will the Future be?* Grand Oncology Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - September 23, 2010.
151. *Managing Adverse Events in HER2 Positive Metastatic Breast Cancer*. Oncology Nursing In-Service, The Ottawa Hospital Cancer Center, Ottawa, Ontario - July 23, 2010.
152. *Managing patients on new cancer therapies: What family physicians need to know*. Individualized Cancer Care: From Prevention to Survivorship, Ottawa, Ontario – June 2010.
153. *Preparation and Administration of Taxanes: Docetaxel, Paclitaxel and Nab-Paclitaxel*. Champlain LHIN Pharmacists Education Session, The Ottawa Hospital, Ottawa, Ontario - May 20, 2010.
154. *When to say No! Aligning your activities with your career direction and maintain a healthy balance between work and home life*. Annual Faculty of Medicine Development Day, University of Ottawa, Ottawa, Ontario - March 4, 2010.

155. *San Antonio Breast Cancer Symposium (SABCS) 2009 Update*. Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - February 2010.
156. *Managing Patients on New Chemotherapy Therapies – What the family physician needs to know!* Internal Medicine Day, Ottawa, Ontario - January 22, 2010.
157. *Approaches to the Systemic Management of Locally Advanced Breast Cancer*. Oncology Training Program, The University of Ottawa, Ottawa, Ontario – October 2009.
158. *Long-term complications of treatments in breast cancer*. Academic Half Day, Subspecialty, Combined Oncology Lecture, Ottawa, Ontario – October 2009.
159. *Approaches to the Treatment of Locally Advanced and Inflammatory Breast Cancer/Clinical Scenarios*. Combined Oncology Residents, The Ottawa Hospital, Ottawa, Ontario – October 2009.
160. *Introduction to the care of individuals receiving systemic therapy*. Multidisciplinary Cancer Care Regional Conference, Ottawa, Ontario – September 2009.
161. *Locally Advanced Breast Cancer (LABC)*. The Great Breast Cancer Debate, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - June 2009.
162. *Targeted Therapy in Breast Cancer*. Academic Half Day, University of Ottawa Medical and Radiation Oncology Residents, Ottawa, Ontario – July 2009.
163. *National Cancer Institute of Canada (NCIC) Spring Meeting Update*. Breast Cancer Disease Site Group, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - May 29, 2009.
164. *Optimizing Intervention: Case Studies in the Adjuvant Treatment of Breast Cancer*. Resident & Fellow Workshop, Ottawa, Ontario – May 2009.
165. *Anticipating Neutropenia in Chemotherapy: insights into prevention and treatment*. Oncology Nurses Lunch & Learn, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - March 2009.
166. *San Antonio Breast Cancer Symposium (2008) Update*. Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - January 9, 2009.
167. *Identifying molecular mediators controlling the formation of bone metastases in patients with breast cancer*. Breast Cancer Disease Site Group, The Ottawa Hospital Cancer Centre, Ottawa, Ontario – January 2009.
168. *The Ontario Cancer Research Ethics Board (OCREB): A Modified Centralized Model of Ethics Review*. Department of Medicine Grand Rounds, The University of Ottawa, Ottawa, Ontario - October 16, 2008.
169. *Targeted therapy for ErB2(HER2) positive breast cancer*. Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario – October 2008.
170. *The Changing Landscape of Breast Cancer*. Family Practice Day, Ottawa, Ontario – October 2008.
171. *Adjuvant Hormonal Therapy in Breast Cancer: The Aches and Pains!* Breast Brainstorming Session, Ottawa, Ontario – August 2008.
172. *Lessons learned over 25 years – Breast Cancer*. Medical Oncology 25th Reunion, Montebello, Quebec – June 2008.
173. *Locally Advanced Breast Cancer*. The Ottawa Hospital Breast Cancer Journal Club, Ottawa, Ontario - June 28, 2008.
174. *Breast Cancer Highlights: American Society of Clinical Oncology (ASCO) 2008*. Oncology Grand Rounds, The Ottawa Hospital Cancer Centre, Ottawa, Ontario - June 26, 2008.
175. *Early Stage Breast Cancer – What Surgeons Need to Know!* Surgical Oncology Residents, Ottawa, Ontario – March 2008.

176. *Chemotherapy for breast cancer*. Surgical Resident's Course, The Ottawa Hospital, Ottawa, Ontario – 2008.
177. *Centralized Trial Management for Early Phase Drug Development*. Canadian Phase I Research Program, Ottawa, Ontario – December 2007.
178. Medical Oncology Residents' Course, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario – December 2007.
179. *Progress in Systemic Therapy of Early Disease & Triple Negative Breast Cancer: A Separate Entity*. Fall Breast Cancer Symposium, Ottawa, Ontario – Nov 2007.
180. *Approaches in Adjuvant Systemic Management in Early Stage Breast Cancer*. Medical Oncology Residents, The Ottawa Hospital, Ottawa, Ontario – November 2007.
181. Medical Oncology Resident's Course, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario – September 2007.
182. *Overview of Neoadjuvant Chemo Role of Radiation Therapy following Cytoreduction surgery*. Champlain Regional Breast Cancer Surgery Journal Club, Ottawa, Ontario, April 2007
183. *MBC – Therapeutic Treatment Options*. Presented to Oncology Breast Cancer Specialists, Ottawa, Ontario, November 2006
184. *Bone Health in Women taking Aromatase Inhibitors – ASCO 2006 Update*. Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, June 2006
185. *Prevention of Anthracycline-induced cardiotoxicity with L-carnitine in Patients with Breast Cancer*. Research & Development Rounds, The Ottawa Hospital, Ottawa, Ontario, April, 2006
186. *Metastatic Breast Cancer – Treatment Options in 2006* Presented to Oncology Nurses, The Ottawa Hospital, Ottawa, Ontario, February, 2006
187. *Adjuvant Chemotherapy: Weighing the Benefits and Risks*. Invited Speaker, Fall Breast Cancer Conference – *A Community of Caring*, Ottawa, Ontario, October, 2005
188. *Hormonal Therapy – Chaos, Confusion and Common Sense*. Invited Speaker, Fall Breast Cancer Conference – *A Community of Caring*, Ottawa, Ontario, October, 2005
189. *Anemia – Treatment Options and the Ottawa Hospital Regional Cancer Centre Clinical Experience*. Oncology Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, October, 2005
190. *Anemia* CME Accredited Talk presented at The Ottawa Hospital, Ottawa, Ontario, September, 2005
191. *New Treatment Options in Early Stage Breast Cancer*. Medical Oncology Nurses, The Ottawa Hospital, Ottawa, Ontario, September, 2005
192. *Highlights of the World Conference on Lung Cancer*. Oncology Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, July, 2005
193. *ASCO Update 2005*. Presented at Special Oncology Rounds, The Ottawa Hospital, Ottawa, Ontario, June, 2005
194. *Clinical Trials at the Ottawa Hospital Regional Cancer Centre – What you Should Know?* Presented for Nurses' Week, The Ottawa Hospital, Ottawa, Ontario, May, 2005
195. *Chemotherapy: Essentials & Managing Side Effects*. Family Medicine Update Workshop, Ottawa, Ontario, January, 2005
196. *Benefits/Risk in Endocrine Adjuvant Therapy for Breast Cancer (BEAT)* CME Accredited Program presented in Ottawa, Ontario, January, 2005
197. *Highlights of the 27th Annual San Antonio Breast Cancer Symposium*. Presented at Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, December, 2004

198. *Metastatic Breast Cancer Treatment Challenges*. Presented at Lunch N'Learn In-service to Nurses, The Ottawa Hospital, Ottawa, Ontario, September, 2004
199. *The Agony & The Ecstasy – Multi-Centre Clinical Trials*. Department of Medicine Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, January, 2004
200. *Bone Metastases – What are the Treatment Options*. Presented to Medical Oncology Nurses, The Ottawa Hospital, Ottawa, Ontario, November 2003
201. *Bridging the Gap in Community Oncology Care – From Diagnosis through Survivorship*. Workshop, ORCC Conference Community Talk, Ottawa, Ontario, November 2003
202. *Survivorship: Life after Breast Cancer Treatment*. ORCC Grand Rounds, The Ottawa Hospital, Ottawa, Ontario, October, 2003
203. *Clinical Research at the Ottawa Regional Cancer Centre*. Presented at Lung Retreat, The Ottawa Hospital, Ottawa, Ontario, April 2003
204. *Colorectal Cancer* Regional Family Physician Oncology Group, Thunder Bay, Ontario – Apr 2000
205. *Are They for Your Patient*. Presented to Regional Family Physician Oncology Group, Thunder Bay, Ontario, February 1999
206. *Overview of Clinical Trials*. Radiation Therapists of Northwestern Ontario Regional Cancer Centre, Thunder Bay, Ontario, April 1998
207. *The Estrogen Question*. Presented at Breast Cancer Forum '97, Thunder Bay, Ontario, March 1997
208. *Physician/Patient Communication*. Family Medicine North Residents Academic Half Day, Thunder Bay, Ontario, January, 1997
209. *Medical Aspects of Cancer*. Presented at the Canadian Cancer Society Annual Meeting, Thunder Bay, Ontario, September 1996
210. *Are They for Your Patient* Regional Family Physician Oncology Group, Thunder Bay, Ontario – Feb 1999

PUBLIC PRESENTATIONS & APPEARANCES

1. Celebrating your impact 2016. The Ottawa Hospital Journal. January 2016.
2. CBC 6 o'clock News on World Cancer Day. Interviewed by Adrian Harewood. Ottawa. February 5th, 2016
3. Curing Cancer: Healing Hearts, Presentation to Board of Directors and public. The Ottawa Regional Cancer Foundation. Maplesoft Center, Ottawa, October 21st, 2015
4. The Ottawa Hospital Research Institute – Tender Loving Research Campaign, CFRA, Ottawa, Ontario – June 25, 2015.
5. Bust A Move 2015 – Grand Opening of Pink Lounge, Ottawa, Ontario – February 2015.
6. Breast Cancer Research and Treatment video shoot, Ottawa Regional Cancer Foundation, Ottawa, Ontario - November 2014.
7. Radio Interview, Rabbi Bulka Show, Ottawa, Ontario – December 2013.
8. The Ottawa Cardiac Oncology Program, CQCO Innovation Award Recognition Evening, Toronto, Ontario – November 2013.

9. *Cancer is hard on the heart.* The Ottawa Citizen, Ottawa, Ontario – June 2013.
10. Bust A Move 2013 – Ottawa CTV Morning Live Interview, Medical Oncologist Representative, Ottawa, Ontario – October 2012.
11. *What you need to know about clinical trials.* Clinical Trials Breakfast Board, Ottawa, Ontario – April 2012.
12. Radio Interview, Steve Madley on CFRA – January 2010.
13. *Clinic offers heart care – Cancer patients treated for drug side effects.* The Ottawa Sun, Ottawa, Ontario – 2009.
14. *Keeping abreast of science.* The Ottawa Citizen, Ottawa, Ontario – 2008.
15. *Many women not adhering to breast cancer therapy.* Sudbury Star, Sudbury, Ontario – 2008.
16. *The face of breast cancer today.* Globe & Mail, Toronto, Ontario – 2008.
17. *Breast Cancer.* School Assembly, CIBC Run For The Cure, Elmwood School, Ottawa, Ontario – September 2007.
18. *Breast Cancer – Have we made progress?* Kiwanis Club, Ottawa, Ontario – September 2007.